BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Heathcote EJ. Management of primary biliary cirrhosis. The American Association for the Study of Liver Diseases practice guidelines. Hepatology. 2000;31:1005-1013. [PMID: 10733559 DOI: 10.1053/he.2000.5984] [Cited by in Crossref: 290] [Cited by in F6Publishing: 249] [Article Influence: 13.2] [Reference Citation Analysis]
Number Citing Articles
1 Papatheodoridis GV, Hadziyannis ES, Deutsch M, Hadziyannis SJ. Ursodeoxycholic acid for primary biliary cirrhosis: final results of a 12-year, prospective, randomized, controlled trial. Am J Gastroenterology 2002;97:2063-70. [DOI: 10.1111/j.1572-0241.2002.05923.x] [Cited by in Crossref: 39] [Cited by in F6Publishing: 34] [Article Influence: 2.0] [Reference Citation Analysis]
2 Tajiri K, Shimizu Y. Recent advances in the management of pruritus in chronic liver diseases. World J Gastroenterol 2017; 23(19): 3418-3426 [PMID: 28596678 DOI: 10.3748/wjg.v23.i19.3418] [Cited by in CrossRef: 17] [Cited by in F6Publishing: 15] [Article Influence: 3.4] [Reference Citation Analysis]
3 Kim SY, Kwon YW, Jung IL, Sung JH, Park SG. Tauroursodeoxycholate (TUDCA) inhibits neointimal hyperplasia by suppression of ERK via PKCα-mediated MKP-1 induction. Cardiovasc Res 2011;92:307-16. [PMID: 21840882 DOI: 10.1093/cvr/cvr219] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 1.7] [Reference Citation Analysis]
4 Saracco GM, Evangelista A, Fagoonee S, Ciccone G, Bugianesi E, Caviglia GP, Abate ML, Rizzetto M, Pellicano R, Smedile A. Etiology of chronic liver diseases in the Northwest of Italy, 1998 through 2014. World J Gastroenterol 2016; 22(36): 8187-8193 [PMID: 27688660 DOI: 10.3748/wjg.v22.i36.8187] [Cited by in CrossRef: 33] [Cited by in F6Publishing: 22] [Article Influence: 5.5] [Reference Citation Analysis]
5 Bassari R, Koea JB. Jaundice associated pruritis: A review of pathophysiology and treatment. World J Gastroenterol 2015; 21(5): 1404-1413 [PMID: 25663760 DOI: 10.3748/wjg.v21.i5.1404] [Cited by in CrossRef: 19] [Cited by in F6Publishing: 15] [Article Influence: 2.7] [Reference Citation Analysis]
6 Hirschfield GM, Heathcote EJ. Antimitochondrial antibody-negative primary biliary cirrhosis. Clin Liver Dis. 2008;12:323-331; viii-ix. [PMID: 18456183 DOI: 10.1016/j.cld.2008.02.003] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 1.4] [Reference Citation Analysis]
7 Gao L, Tian X, Liu B, Zhang F. The value of antinuclear antibodies in primary biliary cirrhosis. Clin Exp Med. 2008;8:9-15. [PMID: 18385935 DOI: 10.1007/s10238-008-0150-6] [Cited by in Crossref: 28] [Cited by in F6Publishing: 26] [Article Influence: 2.0] [Reference Citation Analysis]
8 Chen S, Zhu GJ, Deng GH, Zhu Y. Clinical pathology and HLA-DRB1 allele associations of primary biliary cirrhosis and autoimmune cholangitis in Han Chinese. Shijie Huaren Xiaohua Zazhi 2005; 13(20): 2450-2454 [DOI: 10.11569/wcjd.v13.i20.2450] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
9 Shimura K, Miura J, Kawamoto M, Kawaguchi Y, Yamanaka H, Uchigata Y. Genetic differences between type 1 diabetes with and without other autoimmune diseases. Diabetes Metab Res Rev 2018;34:e3023. [DOI: 10.1002/dmrr.3023] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
10 Chazouillères O, Wendum D, Serfaty L, Rosmorduc O, Poupon R. Long term outcome and response to therapy of primary biliary cirrhosis-autoimmune hepatitis overlap syndrome. J Hepatol. 2006;44:400-406. [PMID: 16356577 DOI: 10.1016/j.jhep.2005.10.017] [Cited by in Crossref: 136] [Cited by in F6Publishing: 110] [Article Influence: 8.0] [Reference Citation Analysis]
11 Li P, Lu G, Cui Y, Wu Z, Chen S, Li J, Wen X, Zhang H, Mu S, Zhang F. Association of IL12A Expression Quantitative Trait Loci (eQTL) With Primary Biliary Cirrhosis in a Chinese Han Population. Medicine (Baltimore). 2016;95:e3665. [PMID: 27175695 DOI: 10.1097/md.0000000000003665] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
12 Hu CJ, Li YZ, Zhao GF, Li N, Xu Y, Tong DW, Zhang SL. Screening for specific biomarkers in serum for diagnosis of primary biliary cirrhosis using proteomic fingerprint technology. Shijie Huaren Xiaohua Zazhi 2008; 16(3): 277-283 [DOI: 10.11569/wcjd.v16.i3.277] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
13 Muratori L, Granito A, Muratori P, Pappas G, Bianchi FB. Antimitochondrial antibodies and other antibodies in primary biliary cirrhosis: diagnostic and prognostic value. Clin Liver Dis. 2008;12:261-276; vii. [PMID: 18456179 DOI: 10.1016/j.cld.2008.02.009] [Cited by in Crossref: 49] [Cited by in F6Publishing: 36] [Article Influence: 3.5] [Reference Citation Analysis]
14 Mayo MJ. Primary biliary cirrhosis: the future. Clin Liver Dis. 2003;7:957-969. [PMID: 14594140 DOI: 10.1016/s1089-3261(03)00093-x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
15 Hessheimer AJ, Forner A, Varela M, Bruix J. Metabolic risk factors are a major comorbidity in patients with cirrhosis independent of the presence of hepatocellular carcinoma. Eur J Gastroenterol Hepatol. 2010;22:1239-1244. [PMID: 20505515 DOI: 10.1097/meg.0b013e32833aa19b] [Cited by in Crossref: 14] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
16 Smyk DS, Rigopoulou EI, Bogdanos DP. Potential Roles for Infectious Agents in the Pathophysiology of Primary Biliary Cirrhosis: What’s New? Curr Infect Dis Rep. 2013;15:14-24. [PMID: 23188623 DOI: 10.1007/s11908-012-0304-2] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 1.7] [Reference Citation Analysis]
17 Lemmers A, Moreno C, Gustot T, Maréchal R, Degré D, Demetter P, de Nadai P, Geerts A, Quertinmont E, Vercruysse V, Le Moine O, Devière J. The interleukin-17 pathway is involved in human alcoholic liver disease. Hepatology 2009;49:646-57. [DOI: 10.1002/hep.22680] [Cited by in Crossref: 251] [Cited by in F6Publishing: 240] [Article Influence: 17.9] [Reference Citation Analysis]
18 Browning J, Combes B, Mayo MJ. Long-term efficacy of sertraline as a treatment for cholestatic pruritus in patients with primary biliary cirrhosis. Am J Gastroenterol. 2003;98:2736-2741. [PMID: 14687826 DOI: 10.1111/j.1572-0241.2003.08662.x] [Cited by in Crossref: 86] [Cited by in F6Publishing: 59] [Article Influence: 4.8] [Reference Citation Analysis]
19 Carithers RL Jr. Primary biliary cirrhosis: specific treatment. Clin Liver Dis. 2003;7:923-939. [PMID: 14594138 DOI: 10.1016/s1089-3261(03)00103-x] [Cited by in Crossref: 9] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
20 Fan LY, Tu XQ, Zhu Y, Pfeiffer T, Feltens R, Stoecker W, Zhong RQ. Genetic association of cytokines polymorphisms with autoimmune hepatitis and primary biliary cirrhosis in the Chinese. World J Gastroenterol 2005; 11(18): 2768-2772 [PMID: 15884119 DOI: 10.3748/wjg.v11.i18.2768] [Cited by in CrossRef: 37] [Cited by in F6Publishing: 37] [Article Influence: 2.2] [Reference Citation Analysis]
21 Xu X, Wang R, Wu R, Yan W, Shi T, Jiang Q, Shi D. Trehalose reduces bone loss in experimental biliary cirrhosis rats via ERK phosphorylation regulation by enhancing autophagosome formation. FASEB j 2020;34:8402-15. [DOI: 10.1096/fj.201902528rrr] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 2.5] [Reference Citation Analysis]
22 Battezzati PM, Zuin M, Crosignani A, Allocca M, Invernizzi P, Selmi C, Villa E, Podda M. Ten-year combination treatment with colchicine and ursodeoxycholic acid for primary biliary cirrhosis: a double-blind, placebo-controlled trial on symptomatic patients: UDCA AND COLCHICINE FOR PBC. Alimentary Pharmacology & Therapeutics 2001;15:1427-34. [DOI: 10.1046/j.1365-2036.2001.01018.x] [Cited by in Crossref: 34] [Cited by in F6Publishing: 28] [Article Influence: 1.6] [Reference Citation Analysis]
23 Liu H, Li P, Li K, Zhou Z, Zhou Y, Leng X, Zhao L, Zhang X. Monoclonal gammopathy in autoimmune diseases: Analysis and follow-up of 160 cases in a tertiary center in China. Clin Immunol 2021;234:108909. [PMID: 34915197 DOI: 10.1016/j.clim.2021.108909] [Reference Citation Analysis]
24 Hu C, Deng C, Zhang S, Song G, Li L, Li X, Wang L, Zhang F, Li Y. Clinical significance and prevalence of anti-Saccharomyces cerevisiae antibody in Chinese patients with primary biliary cirrhosis. Clin Exp Med 2013;13:245-50. [DOI: 10.1007/s10238-012-0207-4] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
25 Dhiman RK, Kurmi R, Thumburu KK, Venkataramarao SH, Agarwal R, Duseja A, Chawla Y. Diagnosis and prognostic significance of minimal hepatic encephalopathy in patients with cirrhosis of liver. Dig Dis Sci. 2010;55:2381-2390. [PMID: 20508990 DOI: 10.1007/s10620-010-1249-7] [Cited by in Crossref: 128] [Cited by in F6Publishing: 119] [Article Influence: 10.7] [Reference Citation Analysis]
26 Bernstein CN, Leslie WD, Leboff MS. AGA technical review on osteoporosis in gastrointestinal diseases. Gastroenterology. 2003;124:795-841. [PMID: 12612917 DOI: 10.1053/gast.2003.50106] [Cited by in Crossref: 264] [Cited by in F6Publishing: 215] [Article Influence: 13.9] [Reference Citation Analysis]
27 European Association for the Study of the Liver. EASL Clinical Practice Guidelines: management of cholestatic liver diseases. J Hepatol. 2009;51:237-267. [PMID: 19501929 DOI: 10.1016/j.jhep.2009.04.009] [Cited by in Crossref: 1087] [Cited by in F6Publishing: 941] [Article Influence: 83.6] [Reference Citation Analysis]
28 Zeman MV, Hirschfield GM. Autoantibodies and liver disease: uses and abuses. Can J Gastroenterol 2010;24:225-31. [PMID: 20431809 DOI: 10.1155/2010/431913] [Cited by in Crossref: 40] [Cited by in F6Publishing: 30] [Article Influence: 3.3] [Reference Citation Analysis]
29 Keaveny AP, Gordon FD, Khettry U. Post-liver transplantation de novo hepatitis with overlap features. Pathol Int. 2005;55:660-664. [PMID: 16185298 DOI: 10.1111/j.1440-1827.2005.01886.x] [Cited by in Crossref: 14] [Cited by in F6Publishing: 9] [Article Influence: 0.8] [Reference Citation Analysis]
30 Li XJ, Yang JH. Clinical and pathological features of primary biliary cirrhotic patients with negative anti-mitochondria antibody M2 subtype. Shijie Huaren Xiaohua Zazhi 2009; 17(16): 1676-1679 [DOI: 10.11569/wcjd.v17.i16.1676] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
31 Chantran Y, Ballot É, Johanet C. Autoantibodies in primary biliary cirrhosis: Antimitochondrial autoantibodies. Clinics and Research in Hepatology and Gastroenterology 2013;37:431-3. [DOI: 10.1016/j.clinre.2013.05.002] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
32 Fan L, Tu X, Zhu Y, Zhou L, Pfeiffer T, Feltens R, Stoecker W, Zhong R. Genetic association of vitamin D receptor polymorphisms with autoimmune hepatitis and primary biliary cirrhosis in the Chinese. J Gastroenterol Hepatol 2005;20:249-55. [PMID: 15683428 DOI: 10.1111/j.1440-1746.2005.03532.x] [Cited by in Crossref: 91] [Cited by in F6Publishing: 87] [Article Influence: 5.4] [Reference Citation Analysis]
33 Pollock G, Minuk GY. Diagnostic considerations for cholestatic liver disease. J Gastroenterol Hepatol 2017;32:1303-9. [PMID: 28106928 DOI: 10.1111/jgh.13738] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 3.4] [Reference Citation Analysis]
34 Liu B, Shi XH, Zhang FC, Zhang W, Gao LX. Antimitochondrial antibody-negative primary biliary cirrhosis: a subset of primary biliary cirrhosis. Liver Int. 2008;28:233-239. [PMID: 18251980 DOI: 10.1111/j.1478-3231.2007.01651.x] [Cited by in Crossref: 31] [Cited by in F6Publishing: 36] [Article Influence: 2.2] [Reference Citation Analysis]
35 Pausch J, Gatzen M. [Treatment of cholestatic hepatic diseases: more than the substitution of fat soluble vitamins?]. Internist (Berl) 2006;47:1239-40, 1242-4. [PMID: 17077981 DOI: 10.1007/s00108-006-1732-6] [Reference Citation Analysis]
36 Glasova H, Beuers U. Extrahepatic manifestations of cholestasis. Journal of Gastroenterology and Hepatology 2002;17:938-48. [DOI: 10.1046/j.1440-1746.2002.02717.x] [Cited by in Crossref: 35] [Cited by in F6Publishing: 23] [Article Influence: 1.8] [Reference Citation Analysis]
37 Volta U, Caio G, Tovoli F, De Giorgio R. Gut-liver axis: an immune link between celiac disease and primary biliary cirrhosis. Expert Rev Gastroenterol Hepatol. 2013;7:253-261. [PMID: 23445234 DOI: 10.1586/egh.13.5] [Cited by in Crossref: 28] [Cited by in F6Publishing: 26] [Article Influence: 3.1] [Reference Citation Analysis]
38 Grundmann SA, Ständer S. Evaluation of chronic pruritus in older patients. Aging Health 2010;6:53-66. [DOI: 10.2217/ahe.09.84] [Cited by in Crossref: 16] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
39 Shen M, Zhang F, Zhang X. Primary biliary cirrhosis complicated with interstitial lung disease: a prospective study in 178 patients. J Clin Gastroenterol. 2009;43:676-679. [PMID: 19247207 DOI: 10.1097/mcg.0b013e31818aa11e] [Cited by in Crossref: 22] [Cited by in F6Publishing: 9] [Article Influence: 1.7] [Reference Citation Analysis]
40 Takegoshi K, Tohyama T, Okada E. A case of advanced primary biliary cirrhosis treated with granulocyte and monocyte apheresis. Ther Apher Dial. 2003;7:468-472. [PMID: 12887733 DOI: 10.1046/j.1526-0968.2003.00085.x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
41 Hempfling W, Grunhage F, Dilger K, Reichel C, Beuers U, Sauerbruch T. Pharmacokinetics and pharmacodynamic action of budesonide in early- and late-stage primary biliary cirrhosis. Hepatology. 2003;38:196-202. [PMID: 12830002 DOI: 10.1053/jhep.2003.50266] [Cited by in Crossref: 109] [Cited by in F6Publishing: 84] [Article Influence: 5.7] [Reference Citation Analysis]
42 Rudic JS, Poropat G, Krstic MN, Bjelakovic G, Gluud C. Bezafibrate for primary biliary cirrhosis. Cochrane Database Syst Rev. 2012;1:CD009145. [PMID: 22259000 DOI: 10.1002/14651858.cd009145.pub2] [Cited by in Crossref: 2] [Cited by in F6Publishing: 7] [Article Influence: 0.2] [Reference Citation Analysis]
43 Wörns MA, Teufel A, Kanzler S, Shrestha A, Victor A, Otto G, Lohse AW, Galle PR, Höhler T. Incidence of HAV and HBV infections and vaccination rates in patients with autoimmune liver diseases. Am J Gastroenterol 2008;103:138-46. [PMID: 17970833 DOI: 10.1111/j.1572-0241.2007.01609.x] [Cited by in F6Publishing: 31] [Reference Citation Analysis]
44 Novak K, Swain MG. Role of methotrexate in the treatment of chronic cholestatic disorders. Clin Liver Dis. 2008;12:81-96, viii. [PMID: 18242498 DOI: 10.1016/j.cld.2007.11.011] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 0.8] [Reference Citation Analysis]
45 Zollner G, Wagner M, Fickert P, Silbert D, Gumhold J, Zatloukal K, Denk H, Trauner M. Expression of bile acid synthesis and detoxification enzymes and the alternative bile acid efflux pump MRP4 in patients with primary biliary cirrhosis. Liver Int. 2007;27:920-929. [PMID: 17696930 DOI: 10.1111/j.1478-3231.2007.01506.x] [Cited by in Crossref: 87] [Cited by in F6Publishing: 79] [Article Influence: 5.8] [Reference Citation Analysis]
46 Muratori P, Muratori L, Cassani F, Terlizzi P, Lenzi M, Rodrigo L, Bianchi FB. Anti-multiple nuclear dots (anti-MND) and anti-Sp100 antibodies in hepa-tic and rheumatological disorders. Clin Exp Immunol. 2002;127:172-175. [PMID: 11882049 DOI: 10.1046/j.1365-2249.2002.01719.x] [Cited by in Crossref: 35] [Cited by in F6Publishing: 32] [Article Influence: 1.8] [Reference Citation Analysis]
47 Cho JG, Lee JH, Hong SH, Lee HN, Kim CM, Kim SY, Yoon KJ, Oh BJ, Kim JH, Jung SY, Asahara T, Kwon SM, Park SG. Tauroursodeoxycholic acid, a bile acid, promotes blood vessel repair by recruiting vasculogenic progenitor cells. Stem Cells 2015;33:792-805. [PMID: 25407160 DOI: 10.1002/stem.1901] [Cited by in Crossref: 31] [Cited by in F6Publishing: 33] [Article Influence: 4.4] [Reference Citation Analysis]
48 Wong GL, Hui AY, Wong VW, Chan FK, Sung JJ, Chan HL. A retrospective study on clinical features and prognostic factors of biopsy-proven primary biliary cirrhosis in Chinese patients. Am J Gastroenterol. 2005;100:2205-2211. [PMID: 16181370 DOI: 10.1111/j.1572-0241.2005.50007.x] [Cited by in Crossref: 25] [Cited by in F6Publishing: 22] [Article Influence: 1.5] [Reference Citation Analysis]
49 Huet PM, Vincent C, Deslaurier J, Coté J, Matsutami S, Boileau R, Huet-van Kerckvoorde J. Portal hypertension and primary biliary cirrhosis: effect of long-term ursodeoxycholic acid treatment. Gastroenterology. 2008;135:1552-1560. [PMID: 18722374 DOI: 10.1053/j.gastro.2008.07.019] [Cited by in Crossref: 53] [Cited by in F6Publishing: 37] [Article Influence: 3.8] [Reference Citation Analysis]
50 Yang L, Zhang H, Jiang YF, Jin QL, Zhang P, Li X, Gao PJ, Niu JQ. Association of Estrogen Receptor Gene Polymorphisms and Primary Biliary Cirrhosis in a Chinese Population: A Case-Control Study. Chin Med J (Engl). 2015;128:3008-3014. [PMID: 26608979 DOI: 10.4103/0366-6999.168964] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
51 Shi GY, Xiernayi·Abuduheilili, Fan XT, Wang HX, Lv RF. Autoimmune liver disease in Xinjiang, China: analysis of 321 cases. Shijie Huaren Xiaohua Zazhi 2010; 18(28): 3035-3039 [DOI: 10.11569/wcjd.v18.i28.3035] [Reference Citation Analysis]
52 Talwalkar JA, Keach JC, Angulo P, Lindor KD. Overlap of autoimmune hepatitis and primary biliary cirrhosis: an evaluation of a modified scoring system. Am J Gastroenterol. 2002;97:1191-1197. [PMID: 12014727 DOI: 10.1111/j.1572-0241.2002.05703.x] [Cited by in Crossref: 90] [Cited by in F6Publishing: 70] [Article Influence: 4.5] [Reference Citation Analysis]
53 Silveira MG, Lindor KD. Treatment of primary biliary cirrhosis: therapy with choleretic and immunosuppressive agents. Clin Liver Dis. 2008;12:425-443; x-xi. [PMID: 18456189 DOI: 10.1016/j.cld.2008.02.008] [Cited by in Crossref: 24] [Cited by in F6Publishing: 20] [Article Influence: 1.7] [Reference Citation Analysis]
54 Boyer JL, Trauner M, Mennone A, Soroka CJ, Cai SY, Moustafa T, Zollner G, Lee JY, Ballatori N. Upregulation of a basolateral FXR-dependent bile acid efflux transporter OSTalpha-OSTbeta in cholestasis in humans and rodents. Am J Physiol Gastrointest Liver Physiol. 2006;290:G1124-G1130. [PMID: 16423920 DOI: 10.1152/ajpgi.00539.2005] [Cited by in Crossref: 192] [Cited by in F6Publishing: 180] [Article Influence: 12.0] [Reference Citation Analysis]
55 Zhang XH, Feng R, Xu LP, Jiang Q, Jiang H, Fu HX, Liu H, Niu T, Wang X, Hu JD, Jiang M, Wang Z, Wang JW, Ma H, Xie YD, Zhu XL, Wang H, Wei L, Huang XJ. Immunosuppressive treatment combined with nucleoside analog is superior to nucleoside analog only in the treatment of severe thrombocytopenia in patients with cirrhosis associated with hepatitis B in China: A multicenter, observational study. Platelets 2015;26:672-9. [PMID: 25397356 DOI: 10.3109/09537104.2014.979339] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
56 Muñoz-Espinosa L, Alarcon G, Mercado-Moreira A, Cordero P, Caballero E, Avalos V, Villarreal G, Senties K, Puente D, Soto J, Esqueda B, Campos G, Martínez M, Jaquez J, Ramirez A, Reyes I, Kershenobich D, Montano-Loza AJ. Performance of the international classifications criteria for autoimmune hepatitis diagnosis in Mexican patients. Autoimmunity 2011;44:543-8. [PMID: 21875376 DOI: 10.3109/08916934.2011.592884] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 1.1] [Reference Citation Analysis]
57 Zhang X, Chen P, Gao H, Hao S, Yang M, Zhao H, Hu J, Ma W, Li L. Bacterial Infection and Predictors of Mortality in Patients with Autoimmune Liver Disease-Associated Acute-On-Chronic Liver Failure. Can J Gastroenterol Hepatol 2018;2018:5108781. [PMID: 29623264 DOI: 10.1155/2018/5108781] [Cited by in Crossref: 3] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
58 Liang Y, Yang Z, Li C, Zhu Y, Zhang L, Zhong R. Characterisation of TNF-related apoptosis-inducing ligand in peripheral blood in patients with primary biliary cirrhosis. Clin Exper Med 2008;8:1-7. [DOI: 10.1007/s10238-008-0149-z] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 1.3] [Reference Citation Analysis]
59 Jones DE. Primary Biliary Cirrhosis. Autoimmunity 2009;37:325-8. [DOI: 10.1080/08916930410001705411] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 0.7] [Reference Citation Analysis]
60 Shao T, Tong Y, Lu S, Jeyarajan AJ, Su F, Dai J, Shi J, Huang J, Hu C, Wu L, Dai X, Cheng Z, Yan J, Huang P, Tian Y, Li S, Chung RT, Chen D. γ-Glutamyltransferase Elevations Are Frequent in Patients With COVID-19: A Clinical Epidemiologic Study. Hepatol Commun 2020. [PMID: 32838106 DOI: 10.1002/hep4.1576] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
61 Gossard AA, Lindor KD. Current and promising therapy for primary biliary cholangitis. Expert Opinion on Pharmacotherapy 2019;20:1161-7. [DOI: 10.1080/14656566.2019.1601701] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
62 Corpechot C, Poujol-Robert A, Wendum D, Galotte M, Chrétien Y, Poupon RE, Poupon R. Biochemical markers of liver fibrosis and lymphocytic piecemeal necrosis in UDCA-treated patients with primary biliary cirrhosis. Liver Int. 2004;24:187-193. [PMID: 15189267 DOI: 10.1111/j.1478-3231.2004.0918.x] [Cited by in Crossref: 32] [Cited by in F6Publishing: 28] [Article Influence: 1.8] [Reference Citation Analysis]
63 Stanca CM, Bach N, Krause C, Tandon N, Freni MA, Gutierrez JA, Bodian C, Lopez J, Berk PD, Bodenheimer HC Jr, Branch AD, Odin JA. Evaluation of fatigue in U.S. patients with primary biliary cirrhosis. Am J Gastroenterol 2005;100:1104-9. [PMID: 15842585 DOI: 10.1111/j.1572-0241.2005.41315.x] [Cited by in Crossref: 44] [Cited by in F6Publishing: 35] [Article Influence: 2.6] [Reference Citation Analysis]
64 Jiang XH, Zhong RQ, Fan XY, Hu Y, An F, Sun JW, Kong XT. Characterization of M2 antibodies in asymptomatic Chinese population. World J Gastroenterol 2003; 9(9): 2128-2131 [PMID: 12970922 DOI: 10.3748/wjg.v9.i9.2128] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.3] [Reference Citation Analysis]
65 Miura T, Ouchida R, Yoshikawa N, Okamoto K, Makino Y, Nakamura T, Morimoto C, Makino I, Tanaka H. Functional modulation of the glucocorticoid receptor and suppression of NF-kappaB-dependent transcription by ursodeoxycholic acid. J Biol Chem. 2001;276:47371-47378. [PMID: 11577102 DOI: 10.1074/jbc.m107098200] [Cited by in Crossref: 99] [Cited by in F6Publishing: 29] [Article Influence: 4.7] [Reference Citation Analysis]
66 Morioka D, Egawa H, Kasahara M, Jo T, Sakamoto S, Ogura Y, Haga H, Takada Y, Shimada H, Tanaka K. Impact of human leukocyte antigen mismatching on outcomes of living donor liver transplantation for primary biliary cirrhosis. Liver Transpl. 2007;13:80-90. [PMID: 16964594 DOI: 10.1002/lt.20856] [Cited by in Crossref: 43] [Cited by in F6Publishing: 33] [Article Influence: 2.9] [Reference Citation Analysis]
67 Alpini G, Kanno N, Phinizy JL, Glaser S, Francis H, Taffetani S, LeSage G. Tauroursodeoxycholate inhibits human cholangiocarcinoma growth via Ca2+-, PKC-, and MAPK-dependent pathways. Am J Physiol Gastrointest Liver Physiol. 2004;286:G973-G982. [PMID: 14701718 DOI: 10.1152/ajpgi.00270.2003] [Cited by in Crossref: 38] [Cited by in F6Publishing: 41] [Article Influence: 2.0] [Reference Citation Analysis]
68 Gallegos-Orozco JF, Vargas HE. Liver transplantation: from Child to MELD. Med Clin North Am. 2009;93:931-950, ix. [PMID: 19577123 DOI: 10.1016/j.mcna.2009.03.010] [Cited by in Crossref: 23] [Cited by in F6Publishing: 15] [Article Influence: 1.8] [Reference Citation Analysis]
69 Maheshwari A, Yoo HY, Thuluvath PJ. Long-term outcome of liver transplantation in patients with PSC: a comparative analysis with PBC. Am J Gastroenterol. 2004;99:538-542. [PMID: 15056099 DOI: 10.1111/j.1572-0241.2004.04050.x] [Cited by in Crossref: 73] [Cited by in F6Publishing: 55] [Article Influence: 4.1] [Reference Citation Analysis]
70 Selmi C, Zuin M, Bowlus CL, Gershwin ME. Anti-mitochondrial antibody-negative primary biliary cirrhosis. Clin Liver Dis. 2008;12:173-185, ix. [PMID: 18242503 DOI: 10.1016/j.cld.2007.11.008] [Cited by in Crossref: 23] [Cited by in F6Publishing: 18] [Article Influence: 1.6] [Reference Citation Analysis]
71 Silveira MG, Suzuki A, Lindor KD. Surveillance for hepatocellular carcinoma in patients with primary biliary cirrhosis. Hepatology 2008;48:1149-56. [DOI: 10.1002/hep.22458] [Cited by in Crossref: 50] [Cited by in F6Publishing: 40] [Article Influence: 3.6] [Reference Citation Analysis]
72 Iwadate H, Ohira H, Saito H, Takahashi A, Rai T, Takiguchi J, Sasajima T, Kobayashi H, Watanabe H, Sato Y. A case of primary biliary cirrhosis complicated by Behçet’s disease and palmoplantar pustulosis. World J Gastroenterol 2006; 12(13): 2136-2138 [PMID: 16610072 DOI: 10.3748/wjg.v12.i13.2136] [Cited by in CrossRef: 11] [Cited by in F6Publishing: 8] [Article Influence: 0.7] [Reference Citation Analysis]
73 Zhu J, Shi Y, Zhou X, Li Z, Huang X, Han Z, Wang J, Wang R, Ding J, Wu K, Han Y, Fan D. Observation on therapeutic efficacy of ursodeoxycholic acid in Chinese patients with primary biliary cirrhosis: a 2-year follow-up study. Front Med 2013;7:255-63. [DOI: 10.1007/s11684-012-0227-1] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
74 Tang YM, Wang JP, Bao WM, Yang JH, Ma LK, Yang J, Chen H, Xu Y, Yang LH, Li W. Urine and serum metabolomic profiling reveals that bile acids and carnitine may be potential biomarkers of primary biliary cirrhosis. Int J Mol Med. 2015;36:377-385. [PMID: 26046127 DOI: 10.3892/ijmm.2015.2233] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 3.0] [Reference Citation Analysis]
75 Blackburn P, Freeston M, Baker CR, Jones DEJ, Newton JL. The role of psychological factors in the fatigue of primary biliary cirrhosis. Liver Int 2007;27:654-61. [DOI: 10.1111/j.1478-3231.2007.01500.x] [Cited by in Crossref: 45] [Cited by in F6Publishing: 40] [Article Influence: 3.0] [Reference Citation Analysis]
76 Sola S, Ma X, Castro RE, Kren BT, Steer CJ, Rodrigues CM. Ursodeoxycholic acid modulates E2F-1 and p53 expression through a caspase-independent mechanism in transforming growth factor beta1-induced apoptosis of rat hepatocytes. J Biol Chem 2003;278:48831-8. [PMID: 14514686 DOI: 10.1074/jbc.M300468200] [Cited by in Crossref: 54] [Cited by in F6Publishing: 13] [Article Influence: 2.8] [Reference Citation Analysis]
77 Oo YH, Neuberger J. Options for treatment of primary biliary cirrhosis. Drugs 2004;64:2261-71. [PMID: 15456326 DOI: 10.2165/00003495-200464200-00001] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 1.0] [Reference Citation Analysis]
78 Hu CJ, Song G, Huang W, Liu GZ, Deng CW, Zeng HP, Wang L, Zhang FC, Zhang X, Jeong JS. Identification of new autoantigens for primary biliary cirrhosis using human proteome microarrays. Mol Cell Proteomics. 2012;11:669-680. [PMID: 22647870 DOI: 10.1074/mcp.m111.015529] [Cited by in Crossref: 62] [Cited by in F6Publishing: 35] [Article Influence: 6.2] [Reference Citation Analysis]
79 Freedman BL, Danford CJ, Patwardhan V, Bonder A. Treatment of Overlap Syndromes in Autoimmune Liver Disease: A Systematic Review and Meta-Analysis. J Clin Med 2020;9:E1449. [PMID: 32414025 DOI: 10.3390/jcm9051449] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
80 Bergasa NV, Mason A, Floreani A, Heathcote J, Swain MG, Jones DEJ, Lindor KM, Bassendine MF, Worman HJ. Primary biliary cirrhosis: Report of a focus study group. Hepatology 2004;40:1013-20. [DOI: 10.1002/hep.1840400434] [Cited by in Crossref: 15] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
81 Bao G, Han Z, Yan Z, Wang Q, Zhou Y, Yao D, Gu M, Chen B, Chen S, Deng A, Zhong R. Increased Siglec-1 expression in monocytes of patients with primary biliary cirrhosis. Immunol Invest 2010;39:645-60. [PMID: 20653431 DOI: 10.3109/08820139.2010.485625] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 1.0] [Reference Citation Analysis]
82 Corpechot C, Carrat F, Bahr A, Chrétien Y, Poupon RE, Poupon R. The effect of ursodeoxycholic acid therapy on the natural course of primary biliary cirrhosis. Gastroenterology. 2005;128:297-303. [PMID: 15685541 DOI: 10.1053/j.gastro.2004.11.009] [Cited by in Crossref: 295] [Cited by in F6Publishing: 230] [Article Influence: 17.4] [Reference Citation Analysis]
83 Suraweera D, Fanous C, Jimenez M, Tong MJ, Saab S. Risk of Cardiovascular Events in Patients with Primary Biliary Cholangitis - Systematic Review. J Clin Transl Hepatol 2018;6:119-26. [PMID: 29951355 DOI: 10.14218/JCTH.2017.00064] [Cited by in Crossref: 3] [Article Influence: 0.8] [Reference Citation Analysis]
84 Rudic JS, Poropat G, Krstic MN, Bjelakovic G, Gluud C. Ursodeoxycholic acid for primary biliary cirrhosis. Cochrane Database Syst Rev. 2012;12:CD000551. [PMID: 23235576 DOI: 10.1002/14651858.CD000551] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 2.3] [Reference Citation Analysis]
85 Zhang Z, Zhai H, Geng J, Yu R, Ren H, Fan H, Shi P. Large-scale survey of gut microbiota associated with MHE via 16S rRNA-based pyrosequencing. Am J Gastroenterol. 2013;108:1601-1611. [PMID: 23877352 DOI: 10.1038/ajg.2013.221] [Cited by in Crossref: 88] [Cited by in F6Publishing: 84] [Article Influence: 9.8] [Reference Citation Analysis]
86 Walker EJ, Hirschfield GM, Xu C, Lu Y, Liu X, Lu Y, Coltescu C, Wang K, Newman WG, Bykerk V. CTLA4/ICOS gene variants and haplotypes are associated with rheumatoid arthritis and primary biliary cirrhosis in the Canadian population. Arthritis Rheum. 2009;60:931-937. [PMID: 19333938 DOI: 10.1002/art.24412] [Cited by in Crossref: 54] [Cited by in F6Publishing: 49] [Article Influence: 4.2] [Reference Citation Analysis]
87 Deng C, Hu C, Wang L, Zhang S, Li P, Wu Z, Chen S, Zhang F, Li Y. Serological comparative proteomics analysis of mitochondrial autoantibody-negative and -positive primary biliary cirrhosis. Electrophoresis. 2015;36:1588-1595. [PMID: 25875855 DOI: 10.1002/elps.201400342] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
88 Ormarsdottir S, Mallmin H, Naessen T, Petren-mallmin M, Broome U, Hultcrantz R, Loof L. An open, randomized, controlled study of transdermal hormone replacement therapy on the rate of bone loss in primary biliary cirrhosis. J Intern Med 2004;256:63-9. [DOI: 10.1111/j.1365-2796.2004.01342.x] [Cited by in Crossref: 37] [Cited by in F6Publishing: 31] [Article Influence: 2.1] [Reference Citation Analysis]
89 Kennedy L, Francis H, Invernizzi P, Venter J, Wu N, Carbone M, Gershwin ME, Bernuzzi F, Franchitto A, Alvaro D, Marzioni M, Onori P, Gaudio E, Sybenga A, Fabris L, Meng F, Glaser S, Alpini G. Secretin/secretin receptor signaling mediates biliary damage and liver fibrosis in early-stage primary biliary cholangitis. FASEB J 2019;33:10269-79. [PMID: 31251081 DOI: 10.1096/fj.201802606R] [Cited by in Crossref: 13] [Cited by in F6Publishing: 6] [Article Influence: 4.3] [Reference Citation Analysis]
90 Zein CO, Angulo P, Lindor KD. When is liver biopsy needed in the diagnosis of primary biliary cirrhosis? Clinical Gastroenterology and Hepatology 2003;1:89-95. [DOI: 10.1053/cgh.2003.50014] [Cited by in Crossref: 57] [Cited by in F6Publishing: 44] [Article Influence: 3.0] [Reference Citation Analysis]
91 Candia R, Norero B, Agüero C, Díaz L, Ortega JP, Wolff R, Hernández-Rocha C, Duarte I, Soza A, Benítez C, Arrese M. Validation of the Simplified Criteria for the Diagnosis of Autoimmune Hepatitis in Chilean-Hispanic Patients. Ann Hepatol 2017;16:772-9. [PMID: 28809732 DOI: 10.5604/01.3001.0010.2787] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
92 Abraham SC, Kamath PS, Eghtesad B, Demetris AJ, Krasinskas AM. Liver transplantation in precirrhotic biliary tract disease: Portal hypertension is frequently associated with nodular regenerative hyperplasia and obliterative portal venopathy. Am J Surg Pathol. 2006;30:1454-1461. [PMID: 17063088 DOI: 10.1097/01.pas.0000213286.65907.ea] [Cited by in Crossref: 52] [Cited by in F6Publishing: 43] [Article Influence: 3.3] [Reference Citation Analysis]
93 Lazaridis KN, Talwalkar JA. Clinical epidemiology of primary biliary cirrhosis: incidence, prevalence, and impact of therapy. J Clin Gastroenterol. 2007;41:494-500. [PMID: 17450033 DOI: 10.1097/01.mcg.0000225653.07932.8f] [Cited by in Crossref: 44] [Cited by in F6Publishing: 40] [Article Influence: 2.9] [Reference Citation Analysis]
94 Qian C, Chen S, Yao D, Wu C, Jiang T, Ke J, Zhou Y, Gu M, Chen B, Deng A, Zhong R. Increased granulysin expression in peripheral blood cells of patients with primary biliary cirrhosis and its clinical implications. J Clin Immunol 2008;28:520-7. [PMID: 18584314 DOI: 10.1007/s10875-008-9207-2] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
95 Colli A, Fraquelli M, Andreoletti M, Marino B, Zuccoli E, Conte D. Severe liver fibrosis or cirrhosis: accuracy of US for detection--analysis of 300 cases. Radiology. 2003;227:89-94. [PMID: 12601199 DOI: 10.1148/radiol.2272020193] [Cited by in Crossref: 209] [Cited by in F6Publishing: 185] [Article Influence: 11.0] [Reference Citation Analysis]
96 Trottier J, Verreault M, Grepper S, Monté D, Bélanger J, Kaeding J, Caron P, Inaba TT, Barbier O. Human UDP-glucuronosyltransferase (UGT)1A3 enzyme conjugates chenodeoxycholic acid in the liver. Hepatology 2006;44:1158-70. [PMID: 17058234 DOI: 10.1002/hep.21362] [Cited by in Crossref: 86] [Cited by in F6Publishing: 83] [Article Influence: 5.4] [Reference Citation Analysis]
97 Murray KF, Carithers RL Jr;  AASLD. AASLD practice guidelines: Evaluation of the patient for liver transplantation. Hepatology. 2005;41:1407-1432. [PMID: 15880505 DOI: 10.1002/hep.20704] [Cited by in Crossref: 519] [Cited by in F6Publishing: 406] [Article Influence: 30.5] [Reference Citation Analysis]
98 Selmi C, Bowlus CL, Gershwin ME, Coppel RL. Primary biliary cirrhosis. Lancet. 2011;377:1600-1609. [PMID: 21529926 DOI: 10.1016/s0140-6736(10)61965-4] [Cited by in Crossref: 193] [Cited by in F6Publishing: 85] [Article Influence: 17.5] [Reference Citation Analysis]
99 Czul F, Peyton A, Levy C. Primary biliary cirrhosis: therapeutic advances. Clin Liver Dis. 2013;17:229-242. [PMID: 23540499 DOI: 10.1016/j.cld.2012.12.003] [Cited by in Crossref: 21] [Cited by in F6Publishing: 23] [Article Influence: 2.3] [Reference Citation Analysis]
100 Muratori P, Granito A, Pappas G, Pendino GM, Quarneti C, Cicola R, Menichella R, Ferri S, Cassani F, Bianchi FB, Lenzi M, Muratori L. The serological profile of the autoimmune hepatitis/primary biliary cirrhosis overlap syndrome. Am J Gastroenterol 2009;104:1420-5. [PMID: 19491855 DOI: 10.1038/ajg.2009.126] [Cited by in Crossref: 73] [Cited by in F6Publishing: 55] [Article Influence: 5.6] [Reference Citation Analysis]
101 Liu C, Shen J, Pan C, Yang L, Mou S, Wang H, Liang Y. MALDI-TOF MS combined with magnetic beads for detecting serum protein biomarkers and establishment of boosting decision tree model for diagnosis of hepatocellular carcinoma. Am J Clin Pathol 2010;134:235-41. [PMID: 20660326 DOI: 10.1309/AJCPA6C6NOGFLYIR] [Cited by in Crossref: 19] [Cited by in F6Publishing: 7] [Article Influence: 1.6] [Reference Citation Analysis]
102 Selmi C, Meroni PL, Gershwin ME. Primary biliary cirrhosis and Sjögren’s syndrome: autoimmune epithelitis. J Autoimmun. 2012;39:34-42. [PMID: 22178199 DOI: 10.1016/j.jaut.2011.11.005] [Cited by in Crossref: 79] [Cited by in F6Publishing: 68] [Article Influence: 7.2] [Reference Citation Analysis]
103 Selmi C, Zuin M, Biondi ML, Invernizzi P, Battezzati PM, Bernini M, Meda F, Gershwin ME, Podda M. Genetic variants of endothelial nitric oxide synthase in patients with primary biliary cirrhosis: Association with disease severity. Journal of Gastroenterology and Hepatology 2003;18:1150-5. [DOI: 10.1046/j.1440-1746.2003.03160.x] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 0.8] [Reference Citation Analysis]
104 Kremer AE, Feramisco J, Reeh PW, Beuers U, Oude Elferink RP. Receptors, cells and circuits involved in pruritus of systemic disorders. Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease 2014;1842:869-92. [DOI: 10.1016/j.bbadis.2014.02.007] [Cited by in Crossref: 58] [Cited by in F6Publishing: 47] [Article Influence: 7.3] [Reference Citation Analysis]
105 Sun Y, Zhang W, Evans JF, Floreani A, Zou Z, Nishio Y, Qi R, Leung PS, Bowlus CL, Gershwin ME. Autotaxin, Pruritus and Primary Biliary Cholangitis (PBC). Autoimmun Rev. 2016;15:795-800. [PMID: 27019050 DOI: 10.1016/j.autrev.2016.03.019] [Cited by in Crossref: 24] [Cited by in F6Publishing: 21] [Article Influence: 4.0] [Reference Citation Analysis]
106 Prince M, Chetwynd A, Newman W, Metcalf JV, James OF. Survival and symptom progression in a geographically based cohort of patients with primary biliary cirrhosis: follow-up for up to 28 years. Gastroenterology 2002;123:1044-51. [PMID: 12360466 DOI: 10.1053/gast.2002.36027] [Cited by in Crossref: 234] [Cited by in F6Publishing: 191] [Article Influence: 11.7] [Reference Citation Analysis]
107 Işık S, Karaman M, Çilaker Micili S, Çağlayan-Sözmen Ş, Bağrıyanık HA, Arıkan-Ayyıldız Z, Uzuner N, Karaman Ö. Beneficial effects of ursodeoxycholic acid via inhibition of airway remodelling, apoptosis of airway epithelial cells, and Th2 immune response in murine model of chronic asthma. Allergol Immunopathol (Madr) 2017;45:339-49. [PMID: 28256288 DOI: 10.1016/j.aller.2016.12.003] [Cited by in Crossref: 13] [Cited by in F6Publishing: 8] [Article Influence: 2.6] [Reference Citation Analysis]
108 Neuberger JM. Primary biliary cirrhosis. Medicine 2007;35:79-82. [DOI: 10.1016/j.mpmed.2006.11.009] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
109 Chantran Y, Ballot E, Johanet C. Autoantibodies in primary biliary cirrhosis: Antinuclear envelope autoantibodies. Clinics and Research in Hepatology and Gastroenterology 2014;38:256-8. [DOI: 10.1016/j.clinre.2013.10.008] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
110 Chen CT, Tseng YC, Yang CW, Lin HH, Chen PJ, Huang TY, Shih YL, Chang WK, Hsieh TY, Chu HC. Increased Risks of Spontaneous Bacterial Peritonitis and Interstitial Lung Disease in Primary Biliary Cirrhosis Patients With Concomitant Sjögren Syndrome. Medicine (Baltimore). 2016;95:e2537. [PMID: 26765478 DOI: 10.1097/md.0000000000002537] [Cited by in Crossref: 9] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
111 Pla X, Vergara M, Gil M, Dalmau B, Cisteró B, Bella RM, Real J. Incidence, prevalence and clinical course of primary biliary cirrhosis in a Spanish community. Eur J Gastroenterol Hepatol 2007;19:859-64. [PMID: 17873609 DOI: 10.1097/MEG.0b013e328277594a] [Cited by in Crossref: 41] [Cited by in F6Publishing: 11] [Article Influence: 2.9] [Reference Citation Analysis]
112 Kheraj R, Tewani SK, Ketwaroo G, Leffler DA. Quality improvement in gastroenterology clinical practice. Clin Gastroenterol Hepatol. 2012;10:1305-1314. [PMID: 22902758 DOI: 10.1016/j.cgh.2012.08.004] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
113 Liu F, Pan ZG, Ye J, Xu D, Guo H, Li GP, Xu KS, Hou XH, Song YH. Primary biliary cirrhosis-autoimmune hepatitis overlap syndrome: simplified criteria may be effective in the diagnosis in Chinese patients. J Dig Dis. 2014;15:660-668. [PMID: 25236944 DOI: 10.1111/1751-2980.12196] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
114 Muratori P, Granito A, Ferri S, Pappas G, Volta U, Menichella R, Bianchi FB, Lenzi M, Muratori L. Multiple nuclear dots and rim-like/membranous IgG isotypes in primary biliary cirrhosis. Autoimmunity 2009;42:224-7. [PMID: 19301204 DOI: 10.1080/08916930802709133] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 0.7] [Reference Citation Analysis]
115 Li Y, Hu C, Leng X, Zhao G, Li N, Xu Y. Promising Diagnostic Biomarkers for Primary Biliary Cirrhosis Identified With Magnetic Beads and MALDI-TOF-MS. Anat Rec 2009;292:455-60. [DOI: 10.1002/ar.20870] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 1.2] [Reference Citation Analysis]
116 Wang Z, Qian R, Wang Y, Mo L, Ju B, Hu N, Wang P, He L, Wang J. QTc interval prolongation in the patients with primary biliary cholangitis. Ann Noninvasive Electrocardiol 2021;:e12925. [PMID: 34854522 DOI: 10.1111/anec.12925] [Reference Citation Analysis]
117 Beuers U, Oude-elferink RP. New light on anion exchangers in primary biliary cirrhosis. Journal of Hepatology 2008;49:881-3. [DOI: 10.1016/j.jhep.2008.09.010] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.5] [Reference Citation Analysis]
118 Zhang Q, Liu Z, Wu S, Duan W, Chen S, Ou X, You H, Kong Y, Jia J. Meta-Analysis of Antinuclear Antibodies in the Diagnosis of Antimitochondrial Antibody-Negative Primary Biliary Cholangitis. Gastroenterol Res Pract. 2019;2019:8959103. [PMID: 31281353 DOI: 10.1155/2019/8959103] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
119 Lazaridis KN, Gores GJ, Lindor KD. Ursodeoxycholic acid ‘mechanisms of action and clinical use in hepatobiliary disorders’. Journal of Hepatology 2001;35:134-46. [DOI: 10.1016/s0168-8278(01)00092-7] [Cited by in Crossref: 256] [Cited by in F6Publishing: 72] [Article Influence: 12.2] [Reference Citation Analysis]
120 Kobayashi M, Furuta K, Kitamura H, Oguchi K, Arai M, Koike S, Nakazawa K. A case of primary biliary cirrhosis that complicated with combined hepatocellular and cholangiocellular carcinoma. Clin J Gastroenterol 2011;4:236-41. [PMID: 26189527 DOI: 10.1007/s12328-011-0223-z] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
121 Hirschfield GM, Liu X, Xu C, Lu Y, Xie G, Lu Y, Gu X, Walker EJ, Jing K, Juran BD. Primary biliary cirrhosis associated with HLA, IL12A, and IL12RB2 variants. N Engl J Med. 2009;360:2544-2555. [PMID: 19458352 DOI: 10.1056/nejmoa0810440] [Cited by in Crossref: 451] [Cited by in F6Publishing: 224] [Article Influence: 34.7] [Reference Citation Analysis]
122 Tandon P, Rowe BH, Vandermeer B, Bain VG. The Efficacy and Safety of Bile Acid Binding Agents, Opioid Antagonists, or Rifampin in the Treatment of Cholestasis-Associated Pruritus. Am J Gastroenterology 2007;102:1528-36. [DOI: 10.1111/j.1572-0241.2007.01200.x] [Cited by in Crossref: 113] [Cited by in F6Publishing: 76] [Article Influence: 7.5] [Reference Citation Analysis]
123 Yu DD, Andrali SS, Li H, Lin M, Huang W, Forman BM. Novel FXR (farnesoid X receptor) modulators: Potential therapies for cholesterol gallstone disease. Bioorg Med Chem 2016;24:3986-93. [PMID: 27372840 DOI: 10.1016/j.bmc.2016.06.039] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 2.2] [Reference Citation Analysis]
124 Reshetnyak VI. Primary biliary cirrhosis: Clinical and laboratory criteria for its diagnosis. World J Gastroenterol 2015; 21(25): 7683-7708 [PMID: 26167070 DOI: 10.3748/wjg.v21.i25.7683] [Cited by in CrossRef: 30] [Cited by in F6Publishing: 26] [Article Influence: 4.3] [Reference Citation Analysis]
125 Zhao SX, Zhang YG, Wang RQ, Li WC, Kong LB, Kong L, Nan YM. A Patient With Primary Biliary Cirrhosis Accompanied by Wilson’s Disease. Hepat Mon. 2016;16:e29077. [PMID: 27148382 DOI: 10.5812/hepatmon.29077] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
126 Boberg KM, Chapman RW, Hirschfield GM, Lohse AW, Manns MP, Schrumpf E; International Autoimmune Hepatitis Group. Overlap syndromes: the International Autoimmune Hepatitis Group (IAIHG) position statement on a controversial issue. J Hepatol. 2011;54:374-385. [PMID: 21067838 DOI: 10.1016/j.jhep.2010.09.002] [Cited by in Crossref: 310] [Cited by in F6Publishing: 246] [Article Influence: 25.8] [Reference Citation Analysis]
127 Zhang H, Jin Z, Cui R, Ding S, Huang Y, Zhou L. Autoimmune metaplastic atrophic gastritis in chinese: a study of 320 patients at a large tertiary medical center. Scand J Gastroenterol 2017;52:150-6. [PMID: 27652682 DOI: 10.1080/00365521.2016.1236397] [Cited by in Crossref: 15] [Cited by in F6Publishing: 19] [Article Influence: 2.5] [Reference Citation Analysis]
128 Sargent S, Fullwood D. Diagnosing and treating a patient with primary biliary cirrhosis. British Journal of Nursing 2008;17:566-70. [DOI: 10.12968/bjon.2008.17.9.29241] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
129 N/A. N/A. Shijie Huaren Xiaohua Zazhi 2005; 13(12): 1478-1481 [DOI: 10.11569/wcjd.v13.i12.1478] [Reference Citation Analysis]
130 Yao Y, Xu ZY, Gao JP, Shen LJ, Wang H, Long Y, Yang JH. Histopathological changes in the liver of patients with autoimmune liver diseases: an analysis of 109 cases. Shijie Huaren Xiaohua Zazhi 2012; 20(7): 605-609 [DOI: 10.11569/wcjd.v20.i7.605] [Reference Citation Analysis]
131 Smyk D, Rigopoulou EI, Zen Y, Abeles RD, Billinis C, Pares A, Bogdanos DP. Role for mycobacterial infection in pathogenesis of primary biliary cirrhosis? World J Gastroenterol 2012; 18(35): 4855-4865 [PMID: 23002357 DOI: 10.3748/wjg.v18.i35.4855] [Cited by in CrossRef: 7] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
132 Sharma R, Prichard D, Majer F, Byrne AM, Kelleher D, Long A, Gilmer JF. Ursodeoxycholic acid amides as novel glucocorticoid receptor modulators. J Med Chem 2011;54:122-30. [PMID: 21158453 DOI: 10.1021/jm100860s] [Cited by in Crossref: 24] [Cited by in F6Publishing: 23] [Article Influence: 2.0] [Reference Citation Analysis]
133 Zollner G, Fickert P, Silbert D, Fuchsbichler A, Marschall HU, Zatloukal K, Denk H, Trauner M. Adaptive changes in hepatobiliary transporter expression in primary biliary cirrhosis. J Hepatol. 2003;38:717-727. [PMID: 12763363 DOI: 10.1016/s0168-8278(03)00096-5] [Cited by in Crossref: 201] [Cited by in F6Publishing: 64] [Article Influence: 11.2] [Reference Citation Analysis]
134 Bellmann R, Graziadei IW, Feistritzer C, Schwaighofer H, Stellaard F, Sturm E, Wiedermann CJ, Joannidis M. Treatment of refractory cholestatic pruritus after liver transplantation with albumin dialysis. Liver Transpl 2004;10:107-14. [DOI: 10.1002/lt.20001] [Cited by in Crossref: 62] [Cited by in F6Publishing: 50] [Article Influence: 3.4] [Reference Citation Analysis]
135 Grünhage F, Heller J, Appenrodt B, Schmitz V, Sauerbruch T. [Medical therapy of complications in liver cirrhosis]. Internist (Berl) 2007;48:1349-57. [PMID: 17992496 DOI: 10.1007/s00108-007-1965-z] [Reference Citation Analysis]
136 Working Subgroup (English version) for Clinical Practice Guidelines for Primary Biliary Cirrhosis. Guidelines for the management of primary biliary cirrhosis: The Intractable Hepatobiliary Disease Study Group supported by the Ministry of Health, Labour and Welfare of Japan. Hepatol Res 2014;44 Suppl S1:71-90. [PMID: 24397841 DOI: 10.1111/hepr.12270] [Cited by in Crossref: 56] [Cited by in F6Publishing: 47] [Article Influence: 7.0] [Reference Citation Analysis]
137 Zeng X, Li S, Tang S, Li X, Zhang G, Li M, Zeng X, Hu C. Changes of Serum IgG Glycosylation Patterns in Primary Biliary Cholangitis Patients. Front Immunol 2021;12:669137. [PMID: 34248947 DOI: 10.3389/fimmu.2021.669137] [Reference Citation Analysis]
138 Tong GD, Tang HH, Wei CS, Chen YJ, He JS, Zhou XZ, Zheng YJ, Zhou DQ. Efficacy of ursodeoxycholic acid combined with Tongdan Decoction () on immunological indices and histopathological changes in primary biliary cirrhosis patients. Chin J Integr Med. 2012;18:16-22. [PMID: 22231705 DOI: 10.1007/s11655-0112-0962-9] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
139 de Liso F, Matinato C, Ronchi M, Maiavacca R. The diagnostic accuracy of biomarkers for diagnosis of primary biliary cholangitis (PBC) in anti-mitochondrial antibody (AMA)-negative PBC patients: a review of literature. Clin Chem Lab Med 2017;56:25-31. [PMID: 28731850 DOI: 10.1515/cclm-2017-0249] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 2.2] [Reference Citation Analysis]
140 Cunha LM, Bittencourt PL, Abrantes-lemos CP, Moreira A, Almeida D, Parana R, Andrade Z. Prevalence of non-organ-specific autoantibodies in a rural community from northeastern Brazil: a population-based study. Human Immunology 2012;73:70-4. [DOI: 10.1016/j.humimm.2011.10.001] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 0.9] [Reference Citation Analysis]
141 Ide R, Oshita A, Nishisaka T, Nakahara H, Aimitsu S, Itamoto T. Primary biliary cholangitis metachronously complicated with combined hepatocellular carcinoma-cholangiocellular carcinoma and hepatocellular carcinoma. World J Hepatol 2017; 9(36): 1378-1384 [PMID: 29359023 DOI: 10.4254/wjh.v9.i36.1378] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
142 Pajares Villarroya R, Castillo Grau P, Manceñido Marcos N, Navajas León F, Hervías Cruz D, Erdozain sosa J, Segura Cabral J. Cirrosis Biliar Primaria Y Embarazo: Beneficio De La Terapia Con Ácido Ursodeoxicólico. Gastroenterología y Hepatología 2003;26:615. [DOI: 10.1016/s0210-5705(03)70416-6] [Cited by in Crossref: 3] [Article Influence: 0.2] [Reference Citation Analysis]
143 Miyake Y, Ikeda F, Takaki A, Nouso K, Yamamoto K. +49A/G polymorphism of cytotoxic T-lymphocyte antigen 4 gene in type 1 autoimmune hepatitis and primary biliary cirrhosis: A meta-analysis. Hepatol Res. 2011;41:151-159. [PMID: 21269385 DOI: 10.1111/j.1872-034X.2010.00757.x] [Cited by in Crossref: 17] [Cited by in F6Publishing: 10] [Article Influence: 1.5] [Reference Citation Analysis]
144 N/A. N/A. Shijie Huaren Xiaohua Zazhi 2004; 12(2): 499-501 [DOI: 10.11569/wcjd.v12.i2.499] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
145 Hohenester S, Oude-Elferink RP, Beuers U. Primary biliary cirrhosis. Semin Immunopathol. 2009;31:283-307. [PMID: 19603170 DOI: 10.1007/s00281-009-0164-5] [Cited by in Crossref: 114] [Cited by in F6Publishing: 96] [Article Influence: 8.8] [Reference Citation Analysis]
146 Durazzo M, Rosina F, Premoli A, Morello E, Fagoonee S, Innarella R, Solerio E, Pellicano R, Rizzetto M. Lack of association between seroprevalence of Helicobacter pylori infection and primary biliary cirrhosis. World J Gastroenterol 2004; 10(21): 3179-3181 [PMID: 15457568 DOI: 10.3748/wjg.v10.i21.3179] [Cited by in CrossRef: 16] [Cited by in F6Publishing: 13] [Article Influence: 0.9] [Reference Citation Analysis]
147 Huang C, Han W, Wang C, Liu Y, Chen Y, Duan Z. Early Prognostic Utility of Gp210 Antibody-Positive Rate in Primary Biliary Cholangitis: A Meta-Analysis. Dis Markers 2019;2019:9121207. [PMID: 31737133 DOI: 10.1155/2019/9121207] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
148 Li P, Lu G, Wang L, Cui Y, Wu Z, Chen S, Li J, Wen X, Zhang H, Mu S. A rare nonsynonymous variant in the lipid metabolic gene HELZ2 related to primary biliary cirrhosis in Chinese Han. Allergy Asthma Clin Immunol. 2016;12:14. [PMID: 27047549 DOI: 10.1186/s13223-016-0120-6] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
149 Tan J, Surti B, Saab S. Pregnancy and cirrhosis. Liver Transpl. 2008;14:1081-1091. [PMID: 18668664 DOI: 10.1002/lt.21572] [Cited by in Crossref: 77] [Cited by in F6Publishing: 56] [Article Influence: 5.5] [Reference Citation Analysis]
150 Weitzel C, Stark D, Kullmann F, Schölmerich J, Holstege A, Falk W. Ursodeoxycholic acid induced activation of the glucocorticoid receptor in primary rat hepatocytes. Eur J Gastroenterol Hepatol 2005;17:169-77. [PMID: 15674094 DOI: 10.1097/00042737-200502000-00007] [Cited by in Crossref: 25] [Cited by in F6Publishing: 21] [Article Influence: 1.5] [Reference Citation Analysis]
151 Pearce RM, Jones DE, Newton JL. Development of an Evidence-Based Patient Information Medium: Empowering Newly Diagnosed Patients With Primary Biliary Cirrhosis. Journal of Visual Communication in Medicine 2011;34:4-13. [DOI: 10.3109/17453054.2011.548794] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
152 Dufour DR. Liver Disease. Tietz Textbook of Clinical Chemistry and Molecular Diagnostics. Elsevier; 2012. pp. 1637-93. [DOI: 10.1016/b978-1-4160-6164-9.00050-0] [Cited by in Crossref: 3] [Article Influence: 0.3] [Reference Citation Analysis]
153 Liu HY, Deng AM, Zhang J, Zhou Y, Yao DK, Tu XQ, Fan LY, Zhong RQ. Correlation of Chlamydia pneumoniae infection with primary biliary cirrhosis. World J Gastroenterol 2005; 11(26): 4108-4110 [PMID: 15996040 DOI: 10.3748/wjg.v11.i26.4108] [Cited by in CrossRef: 12] [Cited by in F6Publishing: 11] [Article Influence: 0.7] [Reference Citation Analysis]
154 Norman GL, Yang CY, Ostendorff HP, Shums Z, Lim MJ, Wang J, Awad A, Hirschfield GM, Milkiewicz P, Bloch DB. Anti-kelch-like 12 and anti-hexokinase 1: novel autoantibodies in primary biliary cirrhosis. Liver Int. 2015;35:642-651. [PMID: 25243383 DOI: 10.1111/liv.12690] [Cited by in Crossref: 43] [Cited by in F6Publishing: 40] [Article Influence: 5.4] [Reference Citation Analysis]
155 Sharma P, Rakela J. Management of pre-liver transplantation patients?Part 1. Liver Transpl 2005;11:124-33. [DOI: 10.1002/lt.20353] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
156 Kumagi T, Guindi M, Fischer SE, Arenovich T, Abdalian R, Coltescu C, Heathcote EJ, Hirschfield GM. Baseline ductopenia and treatment response predict long-term histological progression in primary biliary cirrhosis. Am J Gastroenterol. 2010;105:2186-2194. [PMID: 20502446 DOI: 10.1038/ajg.2010.216] [Cited by in Crossref: 202] [Cited by in F6Publishing: 171] [Article Influence: 16.8] [Reference Citation Analysis]
157 Medina J, Jones EA, García-Monzón C, Moreno-Otero R. Immunopathogenesis of cholestatic autoimmune liver diseases. Eur J Clin Invest. 2001;31:64-71. [PMID: 11168440 DOI: 10.1046/j.1365-2362.2001.00765.x] [Cited by in Crossref: 18] [Cited by in F6Publishing: 14] [Article Influence: 0.9] [Reference Citation Analysis]
158 Shi J, Wu C, Lin Y, Chen YX, Zhu L, Xie WF. Long-term effects of mid-dose ursodeoxycholic acid in primary biliary cirrhosis: a meta-analysis of randomized controlled trials. Am J Gastroenterol. 2006;101:1529-1538. [PMID: 16863557 DOI: 10.1111/j.1572-0241.2006.00634.x] [Cited by in Crossref: 82] [Cited by in F6Publishing: 62] [Article Influence: 5.1] [Reference Citation Analysis]
159 Feramisco JD, Berger TG, Steinhoff M. Innovative management of pruritus. Dermatol Clin 2010;28:467-78. [PMID: 20510757 DOI: 10.1016/j.det.2010.03.004] [Cited by in Crossref: 19] [Cited by in F6Publishing: 15] [Article Influence: 1.6] [Reference Citation Analysis]
160 Montano-Loza AJ, Bhanji RA, Wasilenko S, Mason AL. Systematic review: recurrent autoimmune liver diseases after liver transplantation. Aliment Pharmacol Ther. 2017;45:485-500. [PMID: 27957759 DOI: 10.1111/apt.13894] [Cited by in Crossref: 57] [Cited by in F6Publishing: 39] [Article Influence: 9.5] [Reference Citation Analysis]
161 Park IH, Kim MK, Kim SU. Ursodeoxycholic acid prevents apoptosis of mouse sensory neurons induced by cisplatin by reducing P53 accumulation. Biochem Biophys Res Commun 2008;377:1025-30. [PMID: 18558085 DOI: 10.1016/j.bbrc.2008.06.014] [Cited by in Crossref: 23] [Cited by in F6Publishing: 17] [Article Influence: 1.6] [Reference Citation Analysis]
162 Eugenia Rinella M. Primary biliary cirrhosis. Annals of Hepatology 2006;5:198-200. [DOI: 10.1016/s1665-2681(19)32010-1] [Reference Citation Analysis]
163 Imam MH, Gossard AA, Sinakos E, Lindor KD. Pathogenesis and management of pruritus in cholestatic liver disease. J Gastroenterol Hepatol. 2012;27:1150-1158. [PMID: 22413872 DOI: 10.1111/j.1440-1746.2012.07109.x] [Cited by in Crossref: 36] [Cited by in F6Publishing: 25] [Article Influence: 3.6] [Reference Citation Analysis]
164 Taniguchi E, Harada M, Kawaguchi T, Koga H, Kumemura H, Hanada S, Shishido S, Baba S, Kumashiro R, Ueno T, Sakisaka S, Sata M. Expression of uncoupling protein-2 in biliary epithelial cells in primary biliary cirrhosis: UCP-2 in PBC. Liver 2002;22:451-8. [DOI: 10.1034/j.1600-0676.2002.01700.x] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.4] [Reference Citation Analysis]
165 Marzioni M, Glaser S, Francis H, Marucci L, Benedetti A, Alvaro D, Taffetani S, Ueno Y, Roskams T, Phinizy JL, Venter J, Fava G, Lesage GD, Alpini G. Autocrine/paracrine regulation of the growth of the biliary tree by the neuroendocrine hormone serotonin. Gastroenterology 2005;128:121-37. [PMID: 15633129 DOI: 10.1053/j.gastro.2004.10.002] [Cited by in Crossref: 92] [Cited by in F6Publishing: 88] [Article Influence: 5.4] [Reference Citation Analysis]
166 Benetti A, Crosignani A, Varenna M, Giussani CS, Allocca M, Zuin M, Podda M, Battezzati PM. Primary biliary cirrhosis is not an additional risk factor for bone loss in women receiving regular calcium and vitamin D supplementation: a controlled longitudinal study. J Clin Gastroenterol 2008;42:306-11. [PMID: 18223492 DOI: 10.1097/01.mcg.0000248017.31386.39] [Cited by in Crossref: 5] [Cited by in F6Publishing: 12] [Article Influence: 0.4] [Reference Citation Analysis]
167 Kremer AE, Oude Elferink RP, Beuers U. Pathophysiology and current management of pruritus in liver disease. Clin Res Hepatol Gastroenterol. 2011;35:89-97. [PMID: 21809485 DOI: 10.1016/j.clinre.2010.10.007] [Cited by in Crossref: 66] [Cited by in F6Publishing: 57] [Article Influence: 6.0] [Reference Citation Analysis]
168 Keller J, Frederking D, Layer P. The spectrum and treatment of gastrointestinal disorders during pregnancy. Nat Rev Gastroenterol Hepatol 2008;5:430-43. [DOI: 10.1038/ncpgasthep1197] [Cited by in Crossref: 31] [Cited by in F6Publishing: 16] [Article Influence: 2.2] [Reference Citation Analysis]
169 Shen M, Zhang F, Zhang X. Pulmonary hypertension in primary biliary cirrhosis: a prospective study in 178 patients. Scand J Gastroenterol. 2009;44:219-223. [PMID: 18821172 DOI: 10.1080/00365520802400883] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 0.9] [Reference Citation Analysis]
170 Bian S, Wang L, Fei Y, Liu S, Chen H, Zhang F. The clinical and laboratory features associated with cancer in patients with primary biliary cholangitis: a longitudinal survey-based study. Clin Rheumatol 2021;40:3311-7. [PMID: 33611649 DOI: 10.1007/s10067-021-05657-z] [Reference Citation Analysis]
171 Cholongitas E, Mavrogiannaki A, Papaioannou C, Karagiannis S, Papatheodoridis GV. Pericarditis and possible antiphospholipid syndrome on primary biliary cirrhosis. Annals of Hepatology 2004;3:167-8. [DOI: 10.1016/s1665-2681(19)32097-6] [Cited by in Crossref: 3] [Article Influence: 0.2] [Reference Citation Analysis]
172 Ehrlich L, Scrushy M, Meng F, Lairmore TC, Alpini G, Glaser S. Biliary epithelium: A neuroendocrine compartment in cholestatic liver disease. Clin Res Hepatol Gastroenterol 2018;42:296-305. [PMID: 29678444 DOI: 10.1016/j.clinre.2018.03.009] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
173 Malik A, Kardashian AA, Zakharia K, Bowlus CL, Tabibian JH. Preventative care in cholestatic liver disease: Pearls for the specialist and subspecialist. Liver Res 2019;3:118-27. [PMID: 32042471 DOI: 10.1016/j.livres.2019.04.001] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
174 Kubota J, Ikeda F, Terada R, Kobashi H, Fujioka S, Okamoto R, Baba S, Morimoto Y, Ando M, Makino Y, Taniguchi H, Yasunaka T, Miyake Y, Iwasaki Y, Yamamoto K. Mortality rate of patients with asymptomatic primary biliary cirrhosis diagnosed at age 55 years or older is similar to that of the general population. J Gastroenterol 2009;44:1000-6. [PMID: 19562250 DOI: 10.1007/s00535-009-0090-2] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 0.8] [Reference Citation Analysis]
175 Silva IS, Ferraz ML, Perez RM, Lanzoni VP, Figueiredo VM, Silva AE. Role of gamma-glutamyl transferase activity in patients with chronic hepatitis C virus infection. J Gastroenterol Hepatol. 2004;19:314-318. [PMID: 14748879 DOI: 10.1111/j.1440-1746.2003.03256.x] [Cited by in Crossref: 46] [Cited by in F6Publishing: 49] [Article Influence: 2.6] [Reference Citation Analysis]
176 Romero-gomez M, Wichmann I, Crespo J, Pares A, Rodrigo L, Alvarez A, Diago M, Pons-romero F, Sanchez-munoz D, Aguilar-reina J, Andrade RJ, Salmeron J, Sanchez-pobre P, Rebollo JM, Martin-vivaldi R, Castellano-megias V, Nunez-roldan A, Bruguera M; Spanish Group for the Study of Autoimmune Cholangitis+. Serum Immunological Profile in Patients with Chronic Autoimmune Cholestasis. Am J Gastroenterology 2004;99:2150-7. [DOI: 10.1111/j.1572-0241.2004.40416.x] [Cited by in Crossref: 15] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
177 Heo JY, Kim SU, Kim BK, Park JY, Kim DY, Ahn SH, Park YN, Ahn SS, Han KH, Kim HS. Use of Wisteria Floribunda Agglutinin-Positive Human Mac-2 Binding Protein in Assessing Risk of Hepatocellular Carcinoma Due to Hepatitis B Virus. Medicine (Baltimore) 2016;95:e3328. [PMID: 27057911 DOI: 10.1097/MD.0000000000003328] [Cited by in Crossref: 20] [Cited by in F6Publishing: 14] [Article Influence: 3.3] [Reference Citation Analysis]
178 Bergasa NV. Update on the Treatment of the Pruritus of Cholestasis. Clinics in Liver Disease 2008;12:219-34. [DOI: 10.1016/j.cld.2007.11.009] [Cited by in Crossref: 23] [Cited by in F6Publishing: 13] [Article Influence: 1.6] [Reference Citation Analysis]
179 Granito A, Muratori P, Muratori L, Pappas G, Cassani F, Worthington J, Ferri S, Quarneti C, Cipriano V, De Molo C, Lenzi M, Chapman RW, Bianchi FB. Antibodies to SS-A/Ro-52kD and centromere in autoimmune liver disease: a clue to diagnosis and prognosis of primary biliary cirrhosis: ANTIBODIES TO SS-A/RO-52KD AND CENTROMERE IN AUTOIMMUNE LIVER DISEASE. Alimentary Pharmacology & Therapeutics 2007;26:831-8. [DOI: 10.1111/j.1365-2036.2007.03433.x] [Cited by in Crossref: 53] [Cited by in F6Publishing: 52] [Article Influence: 3.5] [Reference Citation Analysis]
180 Wong RK, Lim SG, Wee A, Chan YH, Aung MO, Wai CT. Primary biliary cirrhosis in Singapore: evaluation of demography, prognostic factors and natural course in a multi-ethnic population. J Gastroenterol Hepatol 2008;23:599-605. [PMID: 17645483 DOI: 10.1111/j.1440-1746.2007.05058.x] [Cited by in Crossref: 16] [Cited by in F6Publishing: 10] [Article Influence: 1.1] [Reference Citation Analysis]
181 Akamatsu N, Sugawara Y. Primary biliary cirrhosis and liver transplantation. Intractable Rare Dis Res 2012;1:66-80. [PMID: 25343075 DOI: 10.5582/irdr.2012.v1.2.66] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
182 Beuers U. Hepatic overlap syndromes. J Hepatol 2005;42 Suppl:S93-9. [PMID: 15777577 DOI: 10.1016/j.jhep.2004.11.009] [Cited by in Crossref: 36] [Cited by in F6Publishing: 32] [Article Influence: 2.0] [Reference Citation Analysis]
183 Dähnrich C, Pares A, Caballeria L, Rosemann A, Schlumberger W, Probst C, Mytilinaiou M, Bogdanos D, Vergani D, Stöcker W. New ELISA for detecting primary biliary cirrhosis-specific antimitochondrial antibodies. Clin Chem. 2009;55:978-985. [PMID: 19264849 DOI: 10.1373/clinchem.2008.118299] [Cited by in Crossref: 57] [Cited by in F6Publishing: 51] [Article Influence: 4.4] [Reference Citation Analysis]
184 Kuiper EM, Hansen BE, de Vries RA, den Ouden-Muller JW, van Ditzhuijsen TJ, Haagsma EB, Houben MH, Witteman BJ, van Erpecum KJ, van Buuren HR; Dutch PBC Study Group. Improved prognosis of patients with primary biliary cirrhosis that have a biochemical response to ursodeoxycholic acid. Gastroenterology. 2009;136:1281-1287. [PMID: 19208346 DOI: 10.1053/j.gastro.2009.01.003] [Cited by in Crossref: 281] [Cited by in F6Publishing: 244] [Article Influence: 21.6] [Reference Citation Analysis]
185 Wu C, Wang Q, Tian G, Xu X, Yu Y, Wang G. Clinical features of the overlap syndrome of autoimmune hepatitis and primary biliary cirrhosis: retrospective study: . Chinese Medical Journal 2006;119:238-41. [DOI: 10.1097/00029330-200602010-00013] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
186 Juran BD, Lazaridis KN. Genetics of Hepatobiliary Diseases. Clinical Gastroenterology and Hepatology 2006;4:548-57. [DOI: 10.1016/j.cgh.2006.03.004] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
187 Smyk DS, Bogdanos DP, Mytilinaiou MG, Burroughs AK, Rigopoulou EI. Rheumatoid arthritis and primary biliary cirrhosis: cause, consequence, or coincidence? Arthritis 2012;2012:391567. [PMID: 23150824 DOI: 10.1155/2012/391567] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 1.2] [Reference Citation Analysis]
188 Danzer C, Mattner J. Impact of microbes on autoimmune diseases. Arch Immunol Ther Exp (Warsz) 2013;61:175-86. [PMID: 23417246 DOI: 10.1007/s00005-013-0216-3] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
189 Su CW, Hung HH, Huo TI, Huang YH, Li CP, Lin HC, Lee PC, Lee SD, Wu JC. Natural history and prognostic factors of primary biliary cirrhosis in Taiwan: a follow-up study up to 18 years. Liver Int. 2008;28:1305-1313. [PMID: 18346129 DOI: 10.1111/j.1478-3231.2008.01715.x] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 1.2] [Reference Citation Analysis]
190 Allocca M, Crosignani A, Gritti A, Benetti A, Zuin M, Podda M, Battezzati PM. Inadequate dietary intake but not renal tubular acidosis is associated with bone demineralization in primary biliary cirrhosis. Aliment Pharmacol Ther 2007;25:219-27. [PMID: 17229245 DOI: 10.1111/j.1365-2036.2006.03181.x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
191 Rust C, Beuers U. Medical treatment of primary biliary cirrhosis and primary sclerosing cholangitis. Clin Rev Allergy Immunol 2005;28:135-45. [PMID: 15879619 DOI: 10.1385/CRIAI:28:2:135] [Cited by in Crossref: 18] [Cited by in F6Publishing: 6] [Article Influence: 1.1] [Reference Citation Analysis]
192 Paumgartner G. Ursodeoxycholic acid for primary biliary cirrhosis: treat early to slow progression. Journal of Hepatology 2003;39:112-4. [DOI: 10.1016/s0168-8278(03)00243-5] [Cited by in Crossref: 16] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
193 Taguchi M, Kihara Y, Nagashio Y, Yamamoto M, Otsuki M, Harada M. Decreased production of immunoglobulin M and A in autoimmune pancreatitis. J Gastroenterol. 2009;44:1133-1139. [PMID: 19626266 DOI: 10.1007/s00535-009-0106-y] [Cited by in Crossref: 21] [Cited by in F6Publishing: 15] [Article Influence: 1.6] [Reference Citation Analysis]
194 Wang L, Zhang FC, Chen H, Zhang X, Xu D, Li YZ, Wang Q, Gao LX, Yang YJ, Kong F, Wang K. Connective tissue diseases in primary biliary cirrhosis: A population-based cohort study. World J Gastroenterol 2013; 19(31): 5131-5137 [PMID: 23964148 DOI: 10.3748/wjg.v19.i31.5131] [Cited by in CrossRef: 40] [Cited by in F6Publishing: 27] [Article Influence: 4.4] [Reference Citation Analysis]
195 Zhang HA, Wang BM, Zhang MF, Chang YX, Gong YX. Clinicopathological features of autoimmune hepatic diseases: an analysis of 28 cases. Shijie Huaren Xiaohua Zazhi 2008; 16(29): 3338-3342 [DOI: 10.11569/wcjd.v16.i29.3338] [Reference Citation Analysis]
196 Deng C, Li W, Fei Y, Wang L, Chen Y, Zeng X, Zhang F, Li Y. Imbalance of the CD226/TIGIT Immune Checkpoint Is Involved in the Pathogenesis of Primary Biliary Cholangitis. Front Immunol 2020;11:1619. [PMID: 32793241 DOI: 10.3389/fimmu.2020.01619] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
197 Chuang N, Gross RG, Odin JA. Update on the epidemiology of primary biliary cirrhosis. Expert Rev Gastroenterol Hepatol 2011;5:583-90. [PMID: 21910576 DOI: 10.1586/egh.11.66] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
198 Marí-alfonso B, Amengual-guedan MJ, Vergara-gómez M, Simeón-aznar CP, Fonollosa-plà V, Jove-buxeda E, Oliva-morera J, Tolosa-vilella C. Implicación pronóstica de las manifestaciones clínicas extrahepáticas, autoinmunidad y capilaroscopia ungueal microscópica en pacientes con cirrosis biliar primaria. Medicina Clínica 2016;146:8-15. [DOI: 10.1016/j.medcli.2015.02.026] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
199 Kanda T, Yokosuka O, Hirasawa Y, Imazeki F, Nagao K, Saisho H. Occurrence of Autoimmune Hepatitis During the Course of Primary Biliary Cirrhosis: Report of Two Cases. Dig Dis Sci 2006;51:45-6. [DOI: 10.1007/s10620-006-3083-5] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
200 Szalay F. Treatment of primary biliary cirrhosis. J Physiol Paris 2001;95:407-12. [PMID: 11595467 DOI: 10.1016/s0928-4257(01)00055-9] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
201 Jiang XH, Zhong RQ, Yu SQ, Hu Y, Li WW, Kong XT. Construction and expression of a humanized M2 autoantigen trimer and its application in the diagnosis of primary biliary cirrhosis. World J Gastroenterol 2003; 9(6): 1352-1355 [PMID: 12800255 DOI: 10.3748/wjg.v9.i6.1352] [Cited by in CrossRef: 9] [Cited by in F6Publishing: 7] [Article Influence: 0.5] [Reference Citation Analysis]
202 Charatcharoenwitthaya P, Pimentel S, Talwalkar JA, Enders FT, Lindor KD, Krom RA, Wiesner RH. Long-term survival and impact of ursodeoxycholic acid treatment for recurrent primary biliary cirrhosis after liver transplantation. Liver Transpl. 2007;13:1236-1245. [PMID: 17763401 DOI: 10.1002/lt.21124] [Cited by in Crossref: 128] [Cited by in F6Publishing: 91] [Article Influence: 8.5] [Reference Citation Analysis]
203 Flisiak R, Pelszynska M, Prokopowicz D, Rogalska M, Grygoruk U. High concentration of antimitochondrial antibodies predicts progressive primary biliary cirrhosis. World J Gastroenterol 2005; 11(36): 5706-5709 [PMID: 16237770 DOI: 10.3748/wjg.v11.i36.5706] [Cited by in CrossRef: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.4] [Reference Citation Analysis]
204 Wang H, Yosipovitch G. New insights into the pathophysiology and treatment of chronic itch in patients with end-stage renal disease, chronic liver disease, and lymphoma. Int J Dermatol 2010;49:1-11. [PMID: 20465602 DOI: 10.1111/j.1365-4632.2009.04249.x] [Cited by in Crossref: 49] [Cited by in F6Publishing: 36] [Article Influence: 4.1] [Reference Citation Analysis]
205 Qin B, Wei T, Wang L, Ma N, Tang Q, Liang Y, Yang Z, Zhou L, Zhong R. Decreased expression of TIPE2 contributes to the hyperreactivity of monocyte to Toll-like receptor ligands in primary biliary cirrhosis: TIPE2 role in primary biliary cirrhosis. Journal of Gastroenterology and Hepatology 2016;31:1177-83. [DOI: 10.1111/jgh.13251] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.5] [Reference Citation Analysis]
206 Rockey DC, Caldwell SH, Goodman ZD, Nelson RC, Smith AD;  American Association for the Study of Liver Diseases. Liver biopsy. Hepatology. 2009;49:1017-1044. [PMID: 19243014 DOI: 10.1002/hep.22742] [Cited by in Crossref: 1217] [Cited by in F6Publishing: 1042] [Article Influence: 93.6] [Reference Citation Analysis]
207 Montero J, Pozo J, Barrera P, Fraga E, Costán G, Domínguez J, Muntané J, Rodriguez-ariza A, Pleguezuelo M, Rufián S, López-cillero P, de la Mata M. Treatment of Refractory Cholestatic Pruritus With Molecular Adsorbent Recirculating System (MARS). Transplantation Proceedings 2006;38:2511-3. [DOI: 10.1016/j.transproceed.2006.08.052] [Cited by in Crossref: 27] [Cited by in F6Publishing: 21] [Article Influence: 1.7] [Reference Citation Analysis]
208 Han D, Liu J, Jin E, He W. Liver assessment using Gd-EOB-DTPA-enhanced magnetic resonance imaging in primary biliary cholangitis patients. Jpn J Radiol 2019;37:412-9. [PMID: 30798469 DOI: 10.1007/s11604-019-00822-6] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
209 Umeuchi H, Kawashima Y, Aoki CA, Kurokawa T, Nakao K, Itoh M, Kikuchi K, Kato T, Okano K, Gershwin ME, Miyakawa H. Spontaneous scratching behavior in MRL/lpr mice, a possible model for pruritus in autoimmune diseases, and antipruritic activity of a novel κ-opioid receptor agonist nalfurafine hydrochloride. European Journal of Pharmacology 2005;518:133-9. [DOI: 10.1016/j.ejphar.2005.06.019] [Cited by in Crossref: 26] [Cited by in F6Publishing: 22] [Article Influence: 1.5] [Reference Citation Analysis]
210 Scott PJ. Occupational therapy services to enable liver patients to thrive following transplantation. Occup Ther Health Care. 2011;25:240-256. [PMID: 23899078 DOI: 10.3109/07380577.2011.600427] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
211 Hirschfield GM, Kumagi T, Heathcote EJ. Preventative hepatology: minimising symptoms and optimising care. Liver Int 2008;28:922-34. [PMID: 18783540 DOI: 10.1111/j.1478-3231.2008.01816.x] [Cited by in Crossref: 16] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
212 Granito A, Muratori P, Muratori L, Pappas G, Cassani F, Worthington J, Guidi M, Ferri S, DE Molo C, Lenzi M. Antinuclear antibodies giving the ‘multiple nuclear dots’ or the ‘rim-like/membranous’ patterns: diagnostic accuracy for primary biliary cirrhosis. Aliment Pharmacol Ther. 2006;24:1575-1583. [PMID: 17206945 DOI: 10.1111/j.1365-2036.2006.03172.x] [Cited by in Crossref: 33] [Cited by in F6Publishing: 27] [Article Influence: 2.2] [Reference Citation Analysis]
213 Lian JS, Liu W, Hao SR, Chen DY, Wang YY, Yang JL, Jia HY, Huang JR. A serum metabolomic analysis for diagnosis and biomarker discovery of primary biliary cirrhosis and autoimmune hepatitis. Hepatobiliary Pancreat Dis Int 2015;14:413-21. [PMID: 26256087 DOI: 10.1016/s1499-3872(15)60393-9] [Cited by in Crossref: 15] [Cited by in F6Publishing: 8] [Article Influence: 2.5] [Reference Citation Analysis]
214 Qiu D, Wang Q, Wang H, Xie Q, Zang G, Jiang H, Tu C, Guo J, Zhang S, Wang J. Validation of the simplified criteria for diagnosis of autoimmune hepatitis in Chinese patients. J Hepatol. 2011;54:340-347. [PMID: 21056494 DOI: 10.1016/j.jhep.2010.06.032] [Cited by in Crossref: 65] [Cited by in F6Publishing: 62] [Article Influence: 5.4] [Reference Citation Analysis]
215 Chan CW, Gunsar F, Feudjo M, Rigamonti C, Vlachogiannakos J, Carpenter JR, Burroughs AK. Long-term ursodeoxycholic acid therapy for primary biliary cirrhosis: a follow-up to 12 years. Aliment Pharmacol Ther 2005;21:217-26. [PMID: 15691295 DOI: 10.1111/j.1365-2036.2005.02318.x] [Cited by in Crossref: 26] [Cited by in F6Publishing: 20] [Article Influence: 1.5] [Reference Citation Analysis]
216 Mela M, Mancuso A, Burroughs AK. Review article: pruritus in cholestatic and other liver diseases. Aliment Pharmacol Ther. 2003;17:857-870. [PMID: 12656688 DOI: 10.1046/j.1365-2036.2003.01458.x] [Cited by in Crossref: 89] [Cited by in F6Publishing: 64] [Article Influence: 4.7] [Reference Citation Analysis]
217 Liu B, Zhang FC, Zhang ZL, Zhang W, Gao LX. Interstitial lung disease and Sjögren’s syndrome in primary biliary cirrhosis: a causal or casual association? Clin Rheumatol. 2008;27:1299-1306. [PMID: 18512115 DOI: 10.1007/s10067-008-0917-x] [Cited by in Crossref: 18] [Cited by in F6Publishing: 14] [Article Influence: 1.3] [Reference Citation Analysis]
218 Hu Z, Huang Y, Liu Y, Sun Y, Zhou Y, Gu M, Chen Y, Xia R, Chen S, Deng A, Zhong R. β-Arrestin 1 modulates functions of autoimmune T cells from primary biliary cirrhosis patients. J Clin Immunol 2011;31:346-55. [PMID: 21243522 DOI: 10.1007/s10875-010-9492-4] [Cited by in Crossref: 27] [Cited by in F6Publishing: 23] [Article Influence: 2.5] [Reference Citation Analysis]
219 Trauner M, Boyer JL. Cholestatic syndromes: . Current Opinion in Gastroenterology 2001;17:242-56. [DOI: 10.1097/00001574-200105000-00007] [Cited by in Crossref: 11] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
220 Bian S, Chen H, Wang L, Fei Y, Yang Y, Peng L, Li Y, Zhang F. Cardiac involvement in patients with primary biliary cholangitis: A 14-year longitudinal survey-based study. PLoS One 2018;13:e0194397. [PMID: 29543892 DOI: 10.1371/journal.pone.0194397] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
221 Zhao J, Zhao S, Zhou G, Liang L, Guo X, Mao P, Zhou X, Wang H, Nan Y, Xu D. Altered biliary epithelial cell and monocyte responses to lipopolysaccharide as a TLR ligand in patients with primary biliary cirrhosis. Scand J Gastroenterol. 2011;46:485-494. [PMID: 21275501 DOI: 10.3109/00365521.2010.539624] [Cited by in Crossref: 18] [Cited by in F6Publishing: 20] [Article Influence: 1.6] [Reference Citation Analysis]
222 Rong G, Zhou Y, Xiong Y, Zhou L, Geng H, Jiang T, Zhu Y, Lu H, Zhang S, Wang P, Zhang B, Zhong R. Imbalance between T helper type 17 and T regulatory cells in patients with primary biliary cirrhosis: the serum cytokine profile and peripheral cell population. Clin Exp Immunol 2009;156:217-25. [PMID: 19302244 DOI: 10.1111/j.1365-2249.2009.03898.x] [Cited by in Crossref: 115] [Cited by in F6Publishing: 109] [Article Influence: 8.8] [Reference Citation Analysis]
223 Zakharia K, Tabibian A, Lindor KD, Tabibian JH. Complications, symptoms, quality of life and pregnancy in cholestatic liver disease. Liver Int. 2018;38:399-411. [PMID: 28921801 DOI: 10.1111/liv.13591] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 2.6] [Reference Citation Analysis]
224 Sasaki M, Nakanuma Y. Biliary epithelial apoptosis, autophagy, and senescence in primary biliary cirrhosis. Hepat Res Treat. 2010;2010:205128. [PMID: 21152179 DOI: 10.1155/2010/205128] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.4] [Reference Citation Analysis]
225 Koh C, Zhao X, Samala N, Sakiani S, Liang TJ, Talwalkar JA. AASLD clinical practice guidelines: a critical review of scientific evidence and evolving recommendations. Hepatology 2013;58:2142-52. [PMID: 23775835 DOI: 10.1002/hep.26578] [Cited by in Crossref: 39] [Cited by in F6Publishing: 40] [Article Influence: 4.3] [Reference Citation Analysis]
226 Alallam A, Barth D, Heathcote EJ. Role of plasmapheresis in the treatment of severe pruritus in pregnant patients with primary biliary cirrhosis: case reports. Can J Gastroenterol 2008;22:505-7. [PMID: 18478137 DOI: 10.1155/2008/969826] [Cited by in Crossref: 31] [Cited by in F6Publishing: 28] [Article Influence: 2.2] [Reference Citation Analysis]
227 Lee J, Belanger A, Doucette JT, Stanca C, Friedman S, Bach N. Transplantation trends in primary biliary cirrhosis. Clin Gastroenterol Hepatol. 2007;5:1313-1315. [PMID: 17900996 DOI: 10.1016/j.cgh.2007.07.015] [Cited by in Crossref: 103] [Cited by in F6Publishing: 75] [Article Influence: 6.9] [Reference Citation Analysis]
228 Meng J, Xu H, Liu X, Wu R, Niu J. Increased red cell width distribution to lymphocyte ratio is a predictor of histologic severity in primary biliary cholangitis. Medicine (Baltimore) 2018;97:e13431. [PMID: 30508955 DOI: 10.1097/MD.0000000000013431] [Cited by in Crossref: 2] [Article Influence: 0.7] [Reference Citation Analysis]
229 Silveira MG, Lindor KD. Overlap syndromes with autoimmune hepatitis in chronic cholestatic liver diseases. Expert Rev Gastroenterol Hepatol. 2007;1:329-340. [PMID: 19072425 DOI: 10.1586/17474124.1.2.329] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 1.2] [Reference Citation Analysis]
230 Stinton LM, Swain M, Myers RP, Shaheen AA, Fritzler MJ. Autoantibodies to GW bodies and other autoantigens in primary biliary cirrhosis. Clin Exp Immunol. 2011;163:147-156. [PMID: 21091667 DOI: 10.1111/j.1365-2249.2010.04288.x] [Cited by in Crossref: 36] [Cited by in F6Publishing: 29] [Article Influence: 3.0] [Reference Citation Analysis]
231 Stanca CM, Bach N, Allina J, Bodian C, Bodenheimer H, Odin JA. Atorvastatin Does Not Improve Liver Biochemistries or Mayo Risk Score in Primary Biliary Cirrhosis. Dig Dis Sci 2008;53:1988-93. [DOI: 10.1007/s10620-007-0003-2] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 1.3] [Reference Citation Analysis]
232 Su CW, Chan CC, Hung HH, Huo TI, Huang YH, Li CP, Lin HC, Tsay SH, Lee PC, Lee SD. Predictive value of aspartate aminotransferase to alanine aminotransferase ratio for hepatic fibrosis and clinical adverse outcomes in patients with primary biliary cirrhosis. J Clin Gastroenterol. 2009;43:876-883. [PMID: 19247208 DOI: 10.1097/mcg.0b013e31818980ac] [Cited by in Crossref: 16] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
233 Farrell GC. Primary biliary cirrhosis in Asians: less common than in Europeans, but just as depressing. J Gastroenterol Hepatol. 2008;23:508-511. [PMID: 18397481 DOI: 10.1111/j.1440-1746.2008.05379.x] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 0.9] [Reference Citation Analysis]
234 Kremer AE, Beuers U, Oude-Elferink RP, Pusl T. Pathogenesis and treatment of pruritus in cholestasis. Drugs. 2008;68:2163-2182. [PMID: 18840005 DOI: 10.2165/00003495-200868150-00006] [Cited by in Crossref: 77] [Cited by in F6Publishing: 58] [Article Influence: 5.9] [Reference Citation Analysis]
235 Hu C, Deng C, Song G, Zhang W, Zhang S, Li X, Li P, Zhang F, Li Y. Prevalence of autoimmune liver disease related autoantibodies in Chinese patients with primary biliary cirrhosis. Dig Dis Sci. 2011;56:3357-3363. [PMID: 21660486 DOI: 10.1007/s10620-011-1756-1] [Cited by in Crossref: 19] [Cited by in F6Publishing: 21] [Article Influence: 1.7] [Reference Citation Analysis]
236 Tschirner A, von Haehling S, Palus S, Doehner W, Anker SD, Springer J. Ursodeoxycholic acid treatment in a rat model of cancer cachexia. J Cachexia Sarcopenia Muscle 2012;3:31-6. [PMID: 22450540 DOI: 10.1007/s13539-011-0044-4] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 1.7] [Reference Citation Analysis]
237 Faust D, Akoglu B, Ristic G, Milovic V. Ursodeoxycholic acid for treatment of cholestasis in patients with hepatic amyloidosis. Vojnosanit Pregl 2009;66:482-6. [PMID: 19583148 DOI: 10.2298/vsp0906482f] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
238 Meng XD, Xiang GQ, He XH, Wang BY. Etiology and clinical character of liver cirrhosis: an analysis of 178 cases. Shijie Huaren Xiaohua Zazhi 2008; 16(17): 1880-1884 [DOI: 10.11569/wcjd.v16.i17.1880] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
239 Dogra S, Jindal R. Cutaneous manifestations of common liver diseases. J Clin Exp Hepatol 2011;1:177-84. [PMID: 25755383 DOI: 10.1016/S0973-6883(11)60235-1] [Cited by in Crossref: 18] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
240 Bhalerao A, Mannu GS. Management of pruritus in chronic liver disease. Dermatol Res Pract 2015;2015:295891. [PMID: 25861254 DOI: 10.1155/2015/295891] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 1.7] [Reference Citation Analysis]
241 Rudic JS, Poropat G, Krstic MN, Bjelakovic G, Gluud C. Ursodeoxycholic acid for primary biliary cirrhosis. Cochrane Database Syst Rev 2012;12:CD000551. [PMID: 23235576 DOI: 10.1002/14651858.CD000551.pub3] [Cited by in Crossref: 17] [Cited by in F6Publishing: 33] [Article Influence: 1.7] [Reference Citation Analysis]
242 Mansour-Ghanaei F, Taheri A, Froutan H, Ghofrani H, Nasiri-Toosi M, Bagherzadeh AH, Farahvash MJ, Mirmomen S, Ebrahimi-Dariani N, Farhangi E, Pourrasouli Z. Effect of oral naltrexone on pruritus in cholestatic patients. World J Gastroenterol 2006; 12(7): 1125-1128 [PMID: 16534857 DOI: 10.3748/wjg.v12.i7.1125] [Cited by in CrossRef: 49] [Cited by in F6Publishing: 37] [Article Influence: 3.1] [Reference Citation Analysis]
243 Wendum D. [Primary biliary cirrhosis and the overlap syndrome of primary biliary cirrhosis and autoimmune hepatitis]. Ann Pathol 2008;28 Spec No 1:S54-5. [PMID: 18984300 DOI: 10.1016/j.annpat.2008.09.014] [Reference Citation Analysis]
244 Selmi C, Meda F, Kasangian A, Invernizzi P, Tian Z, Lian Z, Podda M, Gershwin ME. Experimental evidence on the immunopathogenesis of primary biliary cirrhosis. Cell Mol Immunol 2010;7:1-10. [PMID: 20029462 DOI: 10.1038/cmi.2009.104] [Cited by in Crossref: 34] [Cited by in F6Publishing: 34] [Article Influence: 2.6] [Reference Citation Analysis]
245 Song G, Hu C, Zhu H, Wang L, Zhang F, Li Y, Wu L. New centromere autoantigens identified in systemic sclerosis using centromere protein microarrays. J Rheumatol. 2013;40:461-468. [PMID: 23418382 DOI: 10.3899/jrheum.120264] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 1.4] [Reference Citation Analysis]
246 Crosignani A, Battezzati PM, Invernizzi P, Selmi C, Prina E, Podda M. Clinical features and management of primary biliary cirrhosis. World J Gastroenterol 2008; 14(21): 3313-3327 [PMID: 18528929 DOI: 10.3748/wjg.14.3313] [Cited by in CrossRef: 31] [Cited by in F6Publishing: 25] [Article Influence: 2.2] [Reference Citation Analysis]
247 Czaja AJ. Overlap syndrome of primary biliary cirrhosis and autoimmune hepatitis: a foray across diagnostic boundaries. J Hepatol 2006;44:251-2. [PMID: 16360230 DOI: 10.1016/j.jhep.2005.11.037] [Cited by in Crossref: 34] [Cited by in F6Publishing: 23] [Article Influence: 2.0] [Reference Citation Analysis]
248 Walker LJ, Newton J, Jones DE, Bassendine MF. Comment on biochemical response to ursodeoxycholic acid and long-term prognosis in primary biliary cirrhosis. Hepatology 2009;49:337-8; author reply 338. [PMID: 19035342 DOI: 10.1002/hep.22670] [Cited by in Crossref: 29] [Cited by in F6Publishing: 26] [Article Influence: 2.2] [Reference Citation Analysis]
249 Robinson L, Newton JL, Jones D, Dawson P. Promoting self-management and adherence with strength and balance training for older people with long-term conditions: a mixed-methods study: Self-management in long-term conditions. J Eval Clin Pract 2014;20:318-26. [DOI: 10.1111/jep.12128] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 1.3] [Reference Citation Analysis]
250 Ghent CN. Percutaneous liver biopsy: reflections and refinements. Can J Gastroenterol 2006;20:75-9. [PMID: 16482231 DOI: 10.1155/2006/452942] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
251 Terg R, Coronel E, Sordá J, Muñoz AE, Findor J. Efficacy and safety of oral naltrexone treatment for pruritus of cholestasis, a crossover, double blind, placebo-controlled study. J Hepatol 2002;37:717-22. [PMID: 12445410 DOI: 10.1016/s0168-8278(02)00318-5] [Cited by in Crossref: 113] [Cited by in F6Publishing: 22] [Article Influence: 5.9] [Reference Citation Analysis]
252 Sun J, Chu YJ, Zhang FB, Zheng C. Correlation among hepatic biopsy pathohistology, expression of LAMP2 and laboratory parameters in patients with primary biliary cirrhosis. Shijie Huaren Xiaohua Zazhi 2014; 22(6): 868-873 [DOI: 10.11569/wcjd.v22.i6.868] [Reference Citation Analysis]
253 Wang D, Zhang H, Liang J, Gu Z, Zhou Q, Fan X, Hou Y, Sun L. CD4+ CD25+ but not CD4+ Foxp3+ T cells as a regulatory subset in primary biliary cirrhosis. Cell Mol Immunol. 2010;7:485-490. [PMID: 20729906 DOI: 10.1038/cmi.2010.40] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 1.5] [Reference Citation Analysis]
254 Roda E, Azzaroli F, Nigro G, Piazza F, Jaboli F, Ferrara F, Liva S, Giovanelli S, Miracolo A, Colecchia A. Improved liver tests and greater biliary enrichment with high dose ursodeoxycholic acid in early stage primary biliary cirrhosis. Dig Liver Dis. 2002;34:523-527. [PMID: 12236487 DOI: 10.1016/s1590-8658(02)80112-8] [Cited by in Crossref: 15] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
255 Stauffer AT, Rochat MK, Dick B, Frey FJ, Odermatt A. Chenodeoxycholic acid and deoxycholic acid inhibit 11 beta-hydroxysteroid dehydrogenase type 2 and cause cortisol-induced transcriptional activation of the mineralocorticoid receptor. J Biol Chem 2002;277:26286-92. [PMID: 12015312 DOI: 10.1074/jbc.M201556200] [Cited by in Crossref: 34] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]